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Abstract 
The mixed-lineage leukaemia (MLL) protein is a histone methyl-transferase, that deposits 
the trimethylation mark on Lysine 4 of Histone 3 (H3K4me3)  and that is often mutated in 
certain forms of leukaemia. MLL is normally associated with a cohort of other proteins and 
cofactors, but the mechanisms regulating MLL activity remain unclear. The H3K4me3 mark, 
as deposited by MLL‘s SET domain, which is found in many proteins and mediate lysine-
directed histone methylation, is asociated with actively transcribed genes. Here we examine 
the role of Msk1, a downstream kinase of the MAP-kinase pathway, in regulating MLL1 
activity. Msk1 is known to deposit phosphorylation marks on H3 and these were found on 
MLL1 target genes and the same target site like MLL1. It could be demonstrated that in 
Msk1 knock-down cells the MLL1 target genes are down-regulated. Furthermore during the 
cell cycle MLL1 and Msk1 show the same varying distribution. These findings suggest that 
MLL1 is regulated by extracellular signals via the MAP-kinase pathway and Msk1.  
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1. Introduction 
 
1.1 Epigenetic regulation 
All cells of an individual have the same DNA, which carries the same genetic information. So 
the cell’s identity is defined by its characteristic pattern of gene expression and silencing. 
This pattern has to be maintained through DNA replication, chromatin assembly and DNA 
condensation in mitosis. Furthermore it has to be passed onto daughter cells  and therefore 
can be described as the “cellular memory” of the cell (Turner 2002). There are a variety of 
processes which can effect gene expression programs without altering the DNA sequence, 
referred as “epigenetic mechanisms” (Delcuve, Rastegar et al. 2009). In order to establish a 
stable heritable epigenetic state, an incoming signal from the environment needs to be 
translated, for example by triggering intracellular pathways, which impacts on gene 
expression and the chromatin environment. Finally processes are needed to sustain this 
chromatin state (Berger, Kouzarides et al. 2009). These processes include DNA methylation 
and histone post-translational modifications (Turner 2005; Berger 2007) but also others like 
substitution of histones with histone variants (Khorasanizadeh 2004) or alter nucleosome 
positioning (Henikoff 2008; Schones, Cui et al. 2008). This gives the same cells the ability to 
respond to stimuli in a different way and to proceed with different identities (Jaenisch and 
Bird 2003). Nucleosomes therefore not only compact the genome, but have a more complex 
function as regulators of the genome. As the epigenome can be modulated by 
environmental factors, including chemicals, nutrition and aging, it therefore provides an 
important interface between genes at the environment (Franklin and Mansuy 2010).  
 
1.1.1 Chromatin Organisation 
As shown in Figure 1.1, DNA is packaged in the nucleus by its association with histones to 
form chromatin, which is highly folded, constrained and compacted by histones and non-
histone proteins in a dynamic polymer. Chromatin is the physiological template for all 
eukaryotic genetic information (Woodcock and Ghosh 2011).  The basic unit of DNA packing 
are  the histones, small basic proteins consisting of a globular domain and a flexible and 
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charged NH2-terminus (Jenuwein and Allis 2001). Two copies of each histone protein (H2A, 
H2B, H3 and H4) are assembled into an octamer, around which 145 – 147 base pairs of DNA 
are wrapped in a left handed superhelix. Together they form the nucleosome core (Luger, 
Mader et al. 1997). This nucleoprotein complex is essentially the same in all eukaryotes, is 
one of the most highly conserved structures known, and is regularly repeated in the 
eukaryotic genome (Turner 2005).  
Nucleosomes are assembled into higher-order structures, which in higher eukaryotes are 
stabilized by the positively charged linker histone H1, which acts to maintain the wrapping 
of the negatively charged DNA around the octamer (Zheng and Hayes 2003). It is known that 
the nucleosomes self-assemble into a “30-nm chromatin fibre”, of which probably the 
interphase chromosomes consist of and which further condenses allowing the formation  of 
metaphase chromosomes, where the chromatin is most compacted (Felsenfeld and 
Groudine 2003; Dorigo, Schalch et al. 2004).  
 
1.1.2 Histone Modification and their read-out 
As shown in Figure 1.1 The histone tails, which protrude from the core nucleosome, are the 
target of several covalent modifications (Turner 2005). The post-translational histone 
modifications act basically in two ways. They can either alter the physical properties of the 
histone tail or the nucleosome or they can create new epitopes or binding surfaces for 
histone tails and act so as a ‘histone code’, which can be decoded by effector proteins 
(Jenuwein and Allis 2001; Macdonald, Welburn et al. 2005). More than 70 different sites for 
histone modification and eight main types of modifications have been reported (Taverna, Li 
et al. 2007). They are methylation, acetylation, phosphorylation, ubiquitinylation, 
sumoylation, biotinylation, ADP- ribosylation and prolyl-isomerisation (Lee and Mahadevan 
2009). Despite this variety, the majority of added modifications are acetyl, methyl and 
phosphate groups (Taverna, Li et al. 2007). Distinct modifications act to recruit chromatin- 
associated proteins, which result in different processes occurring in the adjacent DNA (de la 
Cruz, Lois et al. 2005). The many different types of post-translational modifications act to 
both positively and negatively regulate gene expression (Hansen, Nyborg et al. 2010). The 
modifications on histones are dynamic and rapidly changing. They can appear and disappear  
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Figure 1.1: Chromatin organisation  
Figure 1.1: Chromatin organisation. The DNA is wrapped around the nucleosome, which consists of two copies 
of each of the histones H2A, H2B, H3 and H4. The DNA binding is stabilised by the linker histone H1. The 
nucleosome is the fundamental repeating unit of chromatin and supports further assembly into the 30-nm 
chromatin fibre, which can be condensed even more untill it has its most compact form during mitosis. The 
DNA itself can be epigeneticly modified by methylation. The histone tails, which protrude from the core 
nucleosome, also can be target of specific groups on distinct residues (Baber and Rastegar, 2010).   
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on chromatin within minutes of stimulus arriving at the cell surface (Kouzarides 2007). All 
modifications therefore require specialized chromatin modifying proteins.  On one side 
there must be a class of enzymes which deposit the modifications and on the other side 
there must exist a class of enzymes, which remove these marks.  Those two classes of 
enzymes act antagonisticly. The balance between the actions of these enzymes serves as a 
key regulatory mechanism for gene expression and governs numerous developmental 
processes and disease states (Haberland, Johnson et al. 2009). Histone modifications may 
regulate access to the DNA and thus influence nuclear processes. An important issue when 
considering ‘histone-code’-modifications, is how they are translated. Histone modification 
marks provide highly selective binding sites for a series of effector proteins (Mellor 2006). 
Those effector or readout enzymes have in common, that they carry different but highly 
conserved domains, which recognize the modification at certain residues, and are so able to 
interact with chromatin and/or its modified components (Figure 1.2). The bromodomain for 
example functions as an acetyl-lysine binding domain (Mujtaba, Zeng et al. 2007). The 
members of the Royal superfamily are readers of higher lysine methylation, like for example 
the chromodomain. The binding affinities of chromodomains and of bromodomains to their 
respective modified lysines have been shown to be relatively weak, which are thought to 
allow for rapid ‘on-off’ binding (Daniel, Pray-Grant et al. 2005). PHD fingers are also highly 
specialized methyl-lysine binding domain and are often found in close proximity to a 
bromodomain (Mellor 2006).  The combination of modification-binding sites may 
genenerate additional specifities (Taverna, Li et al. 2007). A special role has been identified 
for the protein 14-3-3, which recognizes phosphorylated histone residues. 14-3-3s are well-
conserved and abundant phosphor specific binding proteins, which binds to phosphorylated 
histone H3 (Macdonald, Welburn et al. 2005).  
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Figure 1.2: Histone post-translational modifications and binding partners 
Figure 1.2: Histone post-translational modificatons and binding partners. In order to read the histone code, 
reader proteins contain specified reader modules.  The shown domain groups are known chromatin-
associated modules and the histone marks they have been reported to bind to. The bromodomain 
recognizes acetylated residues, the chromodomain recognizes methylated residues , as well as the PHD 
finger domain. Phosphorylated residues are recognized by 14-3-3 (Taverna et al., 2007). 
8 
 
1.1.3 “Crosstalk” between epigenetic modifications modification 
Although some modifications are clearly linked with  defined functions (acetylation and 
H3K4me3 for example with activation and H3K27me3 with silencing), the precise function of 
most modifications are still unknown (Lee and Mahadevan 2009). The high density of sites 
and various types of histone modification plus additional DNA methylation might indicate 
that many chromatin marks are not recognized independently and that they act together 
(Nightingale, Gendreizig et al. 2007). For example H3S10p is involved in two apparently 
opposed chromatin states (transcriptionally active decondensed euchromatin, versus 
condensed mitotic chromosomes and silent heterochromatin) (Fischle 2008).  It is more 
likely, that modifications influence each other’s functions. This “crosstalk” can appear in 
several forms and therefore chromatin modifications can enhance or block their functions. 
Crosstalk can occur between modifications on a single histone molecule but also between 
histone modifications on different histones, between histone modification and DNA 
methylation or between chromatin modifications on different nucleosomes (Latham and 
Dent 2007; Nightingale, Gendreizig et al. 2007). 
 
1.2 A specific histone methyltransferase - MLL 
MLL, the mixed-lineage leukaemia protein, is a histone methyltransferase, specific for lysine 
4 of histone 3 (Yokoyama, Somervaille et al. 2005). MLL codes for a large protein of ~ 3900 
amino acids, which is cleaved post-translationally into a 320 kDa N-terminus (MLLN) and a 
180 kDa C-terminus (MLLC). The two subunits are bound non-covalently in a tight complex 
(Slany 2005). The domain structure, as shown in Figure 2.1 A, is complex. Two domains, 
FYRN and FYRC, have been found to be important for the hetero-dimerization between 
MLLN and MLLC (Ansari, Mishra et al. 2009). MLLN contains DNA and chromatin targeting 
domains and a repression domain which recruits repression complexes. MLLC contains a 
CBP-binding activation domain and the SET domain and is therefore responsible for the 
methylation of the lysine (Chen, Santillan et al. 2008). Although the MLLN- subunit contains 
repressive domains, in combination with MLLC they result in transcriptional activation (Slany 
2005). 
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A 
B 
Figure 1.3: MLL domain structure and MLL-complex 
Figure 1.3: MLL domain structure and MLL-complex. (A) At the end of the N-terminus, three AT-hooks are 
located, followed by a MT domain with a CxxC signature. Both are involved in non-specific binding to the 
DNA. Close to the MT-domain, the three PHD finger cassette is found. PHDs are usually involved in 
protein-protein interaction, or recognition of specific methyl lysine residues. Bromodomains are involved 
in the recognition of acetylated lysine residues at histone tails. The histone lysine methylation activity is 
located at the SET domain at the C-terminus. The whole protein is post-translationally cleaved at the 
Taspase1 restiction site. The FYRN and FYRC domains together play roles in the association of these 
protein fragments as a complex.  In MLL fusion proteins the C-terminal sequence is replaced by a partner 
protein. The partner proteins convert the truncated MLL into a potent translational activator, and 
leukaemia develops. (B) MLL is a large protein, that is cleaved after translation in two fragments, which 
are bound tightly together.  MLL is associated with a cohort of other factors, so a multi-protein complex is 
formed.  Some of the proteins are involved in binding the complex to the chromatin (WDR5=histone-
binding; menin= DNA-binding). Others are modifiers of chromatin (MLL=methyltransferase; MOF; 
CBP=histone acetyltransferase). 
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Two regions have been identified within MLLN to process the finding of target genes. At the 
extreme N-terminus three AT-hook motifs are present. They bind within the minor groove 
of the double helix and do not require a specific recognition sequence. A second DNA 
binding domain is the MT or methyltransferase-homology domain, which binds to non-
methylated CpG dinucleotides, a feature characteristic of CpG islands in transcriptionally 
competent genes. MLLN also contains a specialized zinc finger structure, termed PHD (plant 
homeodomain) fingers, which are adjacent to the MT region (Slany 2005). However, it is still 
unclear how MLL is recruited to its target promoter elements (Milne, Kim et al. 2002).  In 
MLL1 the PHD fingers are found in close proximity to a bromodomain. This domain may 
target the PHD fingers and influence the specifity of their weak interaction (Mellor 2006; 
Wysocka, Swigut et al. 2006). There is growing evidence that the PHD fingers act as a reader 
of H3K4me3 and therefore may enhance binding or maintenance of gene expression (Milne, 
Kim et al. 2002; Chen, Santillan et al. 2008). 
The transcriptional activation and HMT activity reside in the highly conserved SET domain. 
The SET domain proteins are the major catalytic components of a number of histone 
methyltransferase complexes that effect lysine methylation (Ruthenburg, Wang et al. 2006). 
In mammals six different Set1 homologues have been characterised: MLL1, MLL2, MLL3, 
MLL4, Set1A and Set1B. They all share the same enzymatic activity (H3K4 methylation) but 
they only share up to 30 % of sequence homology (Ansari, Mishra et al. 2009). 
As shown in Figure 2.1 B, MLL is normally associated with a cohort of highly conserved 
cofactors to form a macromolecular complex (Yokoyama, Somervaille et al. 2005). It is still in 
discussion how many cofactors are exactly involved, with numbers varying from five to 29 
other proteins. This reflects that not all the interactions are covalent and that it is not 
always clear whether the proteins are part of the complex or act on the same target site. 
In the complex MLL integrates two major aspects of histone biology: acetylation and 
methylation (Slany 2005). Acetylation is for example provided by the members and histone 
acetyl transferases MOF and CBP. While CBP only interacts transiently with MLL1, MLL1 and 
MOF are recruited together (Dou, Milne et al. 2005). Another member of the complex 
WDR5 recognises dimethyl-K4 on histone 3. It is likely that WDR5 has a ‘peptide 
presentation’ role in the MLL complex involved in H3K4 trimethylation and serves to present 
the K4 side chain to further methylation (Ruthenburg, Wang et al. 2006). Menin, as a further 
member of the complex, is a positive regulator of Hox gene expression and is associated 
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with chromatin on Hox gene loci (Yokoyama, Somervaille et al. 2005).  WDR5 and Menin 
play roles in recruiting the MLL complex to target loci, but the mechanisms remain unclear 
(Ruthenburg, Wang et al. 2006). 
 
1.2.1 MLL and Hox genes 
In mammals, MLL positively regulates multiple loci, including  the clustered homeobox (Hox) 
genes (Milne, Kim et al. 2002). The homeobox genes are master developmental control 
genes that act at the top of genetic hierarchies regulating aspects of morphogenesis and cell 
differentiation in animals. Hox-proteins are crucial to the correct development of bilateral 
organisms (McGinnis, Garber et al. 1984; Hueber, Weiller et al. 2010).   
The mammalian Hox genes are defined by virtue of their homology with the genes of the 
homeotic complex in Drosophila. There are 39 Hox genes organised in four clusters, HoxA, 
HoxB, HoxC and HoxD, each located on a different chromosome and comprising 9-11 genes. 
They encode highly conserved transcription factors with key roles in normal development 
(Barber and Rastegar 2010). 
Hox genes also play a key role in hematopoietic differentiation (Milne, Kim et al. 2002). 
Gene expression analyses of both mouse and human bone marrow samples revealed that 
the majority of Hox genes of the A, B and C clusters are expressed temporally during 
haemopoietic differentiation. The MLL methyl-transferase is required for the proper 
maintenance of Hox gene expression during development. In mouse MLL plays an essential 
role in definitive hematopoiesis by inducing the proliferation and differentiation of 
hematopoietic progenitors through the maintenance of Hox gene expression (Argiropoulos 
and Humphries 2007). MLL regulates specific Hox target loci by direct binding, which 
modulates levels of histone H3 lysine 4 methylation by targeting the intrinsic SET domain to 
the promoters. But how MLL regulates Hox gene expression is poorly understood (Milne, 
Kim et al. 2002). 
During embryogenesis, MLL is required for maintenance of Hox gene expression to establish 
proper body segment identity. In the hematopoietic compartment, lack of MLL is associated 
with reduced expansion of progenitors and decreased Hox gene expression. Conversely, 
hematopoietic cells transformed by MLL oncoproteins consistently hyperexpress several 
Hoxa cluster genes as well as the Meis1 gene, some of which have been shown to be direct 
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targets of MLL and key contributors to the pathologic features of MLL associated leukaemia 
(Yokoyama, Somervaille et al. 2005).  
 
1.2.2 MLL in the context of histone modifications 
Histone modifications are not deposited or recognized in isolation but comprise a complex 
and inter-related collection of modifications at adjacent residues. H3 lysine 4 methylation is 
involved in gene activation and functionally linked with histone H3 acetylation. H3 
acetylation can either facilitate the rate and/or the processivity of HMTase activity or act by 
inhibiting the action of a putative H3K4me3 demethylase. It has been shown, that MLL1’s 
SET1 domain is stimulated in vitro by substrate acetylation (H3K9) together with 
phosphorylation at H3S10 (Nightingale, Gendreizig et al. 2007). 
H3 phosphorylation appears only on a subfraction of nucleosomes and is elicited by ERK and 
p38 MAP kinases, which act through their downstream kinases Msk1/2 (as show in Figure 
2.2). In Msk knock-down cells, an almost complete loss of histone phosphorylation was 
observed (Soloaga, Thomson et al. 2003). Phosphorylation appears at conserved serines on 
histone H3 and H4, but still little is known about histone phosphorylation and gene 
expression. However it was demonstrated that H3 phosphorylation is concomitant with 
early gene induction directly after extracellular stimuli by initiating intracellular signalling 
that rapidly elicit transcription of a subset of genes in the nucleus (Thomson, Clayton et al. 
1999). Beside the correlation of H3 phosphorylation and the induction of immediate-early 
(IE) genes, H3 phosphorylation is also reported in conjunction with other inducible genes 
and oncogenes (Dyson 2005). 
MAPKs (mitogen-activated protein kinase), are a family of evolutionarily conserved 
enzymes, which regulate eukaryotic gene expression in response to extracellular stimuli, like 
cytokines, growth factors and cellular stress. 
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Figure 1.4: Ras-MAPK-MSK pathway and the nucleosomal response 
Figure 1.4: Ras-MAPK-MSK pathway and the nucleosomal response. Extracellular stimuli , like UV 
irradiation or treatment with growth factors  (EGF), trigger intracellular  pathways, which can 
activate either the p38 or ERK kinases. Both kinases can activate the mitogen and stress activated 
protein kinases 1 and 2 (Msk1 and Msk2), which leads to phosphorylation of  histone H3 and the 
activation of  immediate early (IE) genes.  It is been suggested, that H3 phosphorylation is a key 
event linking the  MAPK signaling cascade with chromatin remodeling (Decuve et al., 2009). 
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MAPKs, in context with their downstream kinases, in general phosphorylate transcription 
factors, co-regulators and chromatin proteins to initiate transcriptional changes. They are 
able to form integral components of transcription complexes, act as enzymatically 
functioning structural adaptors, involved in the phosphorylation of local substrates and 
recruitment of chromatin-remodelling complexes, other transcription factors and the 
general transcription machinery (Widmann, Gibson et al. 1999).  
In mammals at least four parallel MAPK cascades exist, that respond to distinct extracellular 
stimuli. H3 phosphorylation is triggered by cascades under the influence of ERK and p38. 
There is evidence for a link between the MAPK cascade and chromatin modification during 
gene induction. MAPKs can provide indirect routes that localize nucleosomal modification at 
inducible genes (for example promoting association of histone acetyl-transferases with 
transcription factors in a phosphorylation-dependent manner) (Edmunds and Mahadevan 
2004). It is been suggested that H3 phosphorylation is a key event linking the MAPK 
signalling cascade with chromatin remodelling (Delcuve, Rastegar et al. 2009).   
Msk phosphorylates H3 at serine 10 and 28 and these marks are targeted to different 
genetic loci and are likely to underpin different functions at these positions. But why? Msk 
does not have an intrinsic specifity for one residue because in vitro they phosphorylate both 
residues. Maybe there is a local restriction of the kinase in vivo to one or the other class of 
loci, where the kinase and other proteins build a complex, so that only one site is available. 
It is also possible, that Msk activity is modulated, by the interaction within different 
complexes, which provides a mechanism to target site specific modifications to particular 
loci (Dyson, Thomson et al. 2005). Nevertheless, Msk mediated H3 phosphorylation is a 
crucial intermediate step between signalling at cell-surface receptors and transcriptional 
reprogramming and it has been suggested that H3 phosphorylation leads to chromatin 
remodelling, giving transcription factors access to regulatory DNA sequences (Drobic, Perez-
Cadahia et al. 2010). Recently it has been demonstrated that Msk1 targeting to the 
endogenous c-fos promoter is sufficient to activate its expression without the need of 
upstream signaling. Moreover, targeting Msk1 to the α-globin promoter induces H3 S28 
phosphorylation and reactivates expression of polycomb-silenced genes (Lau and Cheung 
2010). 
Subsequent studies on the modifying enzymes responsible for generating MLL stimulating 
marks (H3K9ac/S10p) indicate that the histone H3S10 specific kinase Msk1 is present at MLL 
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target loci (Hoxa-loci) (unpublished data). Furthermore Msk1 is a potential component of 
the MLL1 complex. Together this suggests that Msk1 dependant histone H3S10 
phosphorylation contributes to the regulation of MLL methyltransferase activity at Hoxa-
genes. It is hypothesised that this is a key means of regulating MLL activity under normal 
conditions, and that this regulatory mechanism is disrupted by MLL fusion proteins, which 
occur in certain types of leukaemia (Lab Nightingale, data not published).  
 
1.3 Aims 
Msk1 (Mitogen- and Stress- activated Protein Kinase 1) is a protein kinase involved in the 
phosphorylation of H3S10 (Soloaga et al., 2003), but is also downstream of the MAP-kinase 
signalling pathway (Edmunds and Mahadevan, 2004; Huang et al., 2006). Previous data from 
the lab (not published) suggest that H3S10p contributes to Hoxa gene activation. 
Furthermore the sites of Msk1 binding correlated with the modifications deposited by 
proteins of the MLL complex. The data suggested that Msk1 is either part of the MLL 
complex or acted together with the MLL complex to regulate Hoxa gene expression. In this 
project the role of Msk1 on the regulation of MLL1 target genes should be explored. 
Therefore a knock-down in HPC-7 cells needs to be established and the effect of the down 
regulation on known MLL target genes should been examined. To explore the interaction of 
Msk1 and MLL1 Co-IPs were performed. Furthermore it should be investigated how Msk1 
and MLL1 may be involved and therefore a co-localisation study was carried out, which led 
to investigation of cell-cycle dependet changes in Msk1 abundance.
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2. Materials and Methods 
 
2.1 Tissue Culture 
 
2.1.1 Cultivation of HPC7 cells 
HPC7 cells are an immortalised Mouse Embryonic Stem Cell (ESC-like) line (Pinto Do et al., 
1998). HPC7 cells have the capacity to differentiate into several different cell types, notably 
into megakaryocytes, using thrombopoietin (TPO, Peprotech) or monocytes (IL3 and IL6, 
Proprotech). 
Cells were grown in “HPC7 Growth Medium”. Cells were counted every day and diluted to 
1x106 cells per ml in growth medium with recombinant SCF (100 ng/µl, used 1 µl per 1 ml 
medium, Vitrolife). Every second day the medium was replaced with fresh medium. The cells 
were kept at 37⁰C and 5% CO2. 
 
2.1.2 Cultivation of LCL cells 
LCLs are a human lymphoblastoid cell line with a normal karyotype. The cells were grown in 
RPMI medium. After three to four days, dependent on their density, the cells were splitted 
1:4 and set into fresh medium and kept at 37⁰C and 5% CO2. 
HHPC7 Growth Medium: StemPro-34 SFM medium           
       StemPro-34 Nutrient Supplement (Invitrogen)  
               1/100 penicillin (10000 U/ml) (Gibco)  
       1/100 streptomycin (10000 µl/ml) (Gibco)  
1/100 L-glutamine (200 mM) (Invitrogen) 
RPMI Medium: Gibco RPMI 1640 Medium 
    1/100 penicillin (10000 U/ml) (Gibco) 
1/100 streptomycin (10000 µl/ml)  (Gibco) 
  1/100 L-glutamine (200 mM) (Invitrogen)  
  50 ml Fetal Bovine Serum (Invitrogen) 
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2.1.3 Arrest of cells in the Cell Cycle 
In order to arrest cells at certain points in the cell cycle thymidine (Sigma) and colcemid 
(Gibco) were used. Thymidine was added to the medium of the cells in a final concentration 
of 1mM and incubated for 15 hours. It inhibits the cell cycle during S-phase. Colcemid was 
added to the medium of the cells in a final concentration of 0.1  µg/ml and incubated for 15 
hours. It inhibits the cell cycle during at G1-M. 
 
2.2 Protein Methods 
2.2.1 Preparation of whole cell extract  
Cells were collected and washed three times with ice-cold PBS before the cell pellet was 
resuspended in 500 µl Lysis buffer. The mixture was left on a rotating wheel at 4⁰C for 30 
minutes. The mixture was sonicated at high amplitude for 1 minute and afterwards 
centrifuged at 13000 rpm for 10 minutes at 4⁰C. The supernatant was kept. 
 
 
 
PBS:  2.7 mM KCl 
137 mM NaCl 
8.1 mM Na2HPO4 
1.76 mM KH2PO4, pH 7.4  
 
Lysis Buffer:   10 mM Tris, pH 8 
150 mM NaCl  
5 mM EDTA 
0.5 mM EGTA  
1 mM β-Mercaptoethanol    
1% Nonidet P40 
25% Glycerol 
1 tablet protease inhibitor (Roche) per 10 ml 
10 µl PMSF per 10 ml 
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2.2.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
Proteins were separated according to size (Laemmli, 1970). The samples were loaded on an 
acrylamide gel, with a concentration dependent on the size of the proteins to be separated. 
For the detection of Msk1 (~90 kDa MW) and Actin (~50 kDa MW) a 15% SDS gel was 
prepared. The resolving gel was overlaid with 70% ethanol. The ethanol was removed 
before the stacking gel was prepared on top of the resolving gel. Protein samples were 
resuspended in SDS Loading buffer, incubated at 100°C for 10 minutes and loaded onto the 
gel. The gel was electrophoresed at 200 V, 300 mA and 20W, for three hours in a standard 
vertical electrophoresis unit. 
 
 
10% SDS gel:  15ml Bis-acrylamide (30%Acrylamide-0.8% Bis) 
250 µM Tris-HCl, pH 8.8 
300 µl 10% SDS  
100 µl 10% Ammonium Persulfate    
30 µl TEMED made up to 30 ml with distilled water 
 
stacking gel:  1 ml Bis-acrylamide (30% Acrylamide-1.6% Bis)  
250 µM Tris-HCl, pH 6.8 
100 µl 10% SDS 
100 µl 10% Ammonium Persulfate  
10 µl TEMED made up to 10 ml with distilled water 
 
SDS reservoir buffer: 50 mM Tris 
0.384 M glycine 
0.1% SDS 
 
10x SDS Gel Loading Buffer:  20% SDS 
    500 mM Tris, pH 7.6 
    50% Glycerol 
    1 M DTT 
    Bromophenol Blue 
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2.2.3 Immuno-detection of proteins on nitrocellulose membranes (“Western Blot”) 
The separated proteins were transferred (Towbin et al., 1979) onto a Hybond-C 
nitrocellulose membrane (Amersham) for three hours (180V/300mA/20W) using transfer 
buffer. The efficiency of transfer was checked by  Ponceau Red staining. The membrane was 
incubated for one hour or overnight at 4°C in Blocking Buffer. Primary antibodies were 
obtained from commercial sources and are listed below. The membrane was then incubated 
with a first antibody (rabbit or mouse) diluted in 10% milk + 1xPBS + 0.1% Tween for 1 hour 
at room temperature in recommended dilutions. The membrane was washed three times, 
each for 15 minutes, with 10% milk + 1xPBS + 0.1% Tween.  The secondary antibody (Licor 
800 nm-conjugated, anti-rabbit or anti-mouse) was added in a dilution of 1/1000 in 10% 
milk + 1xPBS + 0.1%Tween. Binding was visualised by using the “Odyssey” (Li-Cor) imaging 
system. At 800nm the secondary Licor- Antibody chromophore is acitvated,  permitting 
detection. 
 
Antibody Source Dilution/ Animal 
α-Msk1 Abcam ab82194 1:500 / rabbit 
α-beta Actin Abcam ab8227-50 1:1000 / rabbit 
 Licor 2nd, α-rabbit IgG Rockland 611-131-121 1:1000 / goat 
Licor 2nd, α-mouse IgG Rockland 610-131-121 1:1000 / goat 
Table 2.1: Antibodies used for western blot 
 
 
Transfer buffer:  25 mM Tris 
  192 mM glycine 
20% methanol 
 
Blocking Buffer:  10% dried milk powder 
1 x PBS 
0.1% Tween-20 
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2.2.4 Transfection of HPC7 cells 
The knockdown vector for Msk1 (shRNA_mir vector, Open BioSystms) was transfected into 
HPC7 cells using a commercial procedure (Cell Line Nucleofector® Kit L, Lonza).  A 12-well 
plate was prepared with 1 ml of 2x HPC7 growth medium and 400 µl unsupplemented 
StemPro medium per well. 2x106 cells were required per nucleofection and per well. The 
Lonza Nucleofector Kit was used as the manufacturer’s instructions. Cells were centrifuged 
at 1200 rpm, for 10 min at room temperature and afterwards resuspended in 100 µl of 
Nucleofector Solution L. 2 µg of DNA was added per cell suspension, a plasmid expressing 
GFP (part of the kit) was used as control. The cell suspension was transferred into an 
appropriate cuvette for transfection with the Nucleofector™ II (programme X-001). 500 µl of 
pre-warmed RPMI 1640 medium (Gibco) were immediately added after transfection. The 
cells were then transferred into an Eppendorf tube and left 30 minutes to an hour at 37°C to 
recover. The cells were finally transferred into pre-warmed 12-well plate and incubated for 
the required time period.  
 
 
 
 
 
2x HPC7 growth medium:  11.56 ml StemPro34 SFM medium supplemented with 
StemPro34 Nutrient Supplement (Invitrogen), 
    1/50 penicillin/streptomycin (Gibco) 
1/50 glutamine (Invitrogen) 
13 µl recombinant SCF (Vitrolife) 
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2.3 Functional Analysis 
2.3.1 RNA extraction (Qiagen Kit) 
Total RNA was isolated from HPC7 cells using the QIAGEN Kit (RNase free DNase Set and 
RNeasy® Minikit) according to the manufacturer’s instructions. RNA was quantified using an 
UV/visible spectrophotometer (260 nm, 280 nm). 
 
2.3.2 Real-Time Quantitative PCR (RTQ/PCR) with Reverse Transcription 
This method allowed simultaneous RNA reverse transcription and cDNA amplification in one 
step and was performed according to the manufacturer’s instructions.  The reaction was 
achieved with commercial primers for Msk1 and Actin. The mix per tube contained the 
following: 5 µl of QuantiTech™ Sybr® Green Mix (Qiagen), 0.1 µl of RT-mix (Qiagen), 1 µl of 
primers (Qiagen, Msk1 QT00141554, Act QT01336772), 50 ng RNA template, diluted to 10 µl 
with water. Three analyses were performed for each sample. A control was performed 
without RT-mix, also in triplicate, in order to ensure the non-contamination of the products. 
The samples were loaded in a 384-well optical reaction plate. The RT-qPCR was performed 
on the 7900 HT machine (Applied Biosystems). The programme was set up as following: 
reverse transcription was achieved by heating the samples at 50°C for 30 minutes. The 
samples were then heated at 95°C for 15 minutes, 94°C for 15 seconds for denaturation, 
55°C for 30 seconds for annealing, 72°C for 40 seconds for elongation. The three last steps 
were performed 40 times. Real time PCR employed the characteristics of a fluorescent dye, 
SYBR® Green, which binds to double-strand DNA. PCR products are thus visualized and 
quantified after each cycle of amplification, due to the emission of fluorescence by the 
SYBR® Green.  
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2.3.3 Immunoflouresense Microscopy 
For microscopy, HPC7 and LCL cells were used. They were harvested by centrifuging at 1200 
rpm for 5 minutes at 4°C, washed three times with ice-cold PBS and counted. The cells were 
diluted to a concentration of 1x105cells/ml in KCM. Ethanol washed slides were fixed in 
chambers for the Cytospin. 200 µl of cells were put in the loading chambers and spun down 
for 10 minutes at 1000 rpm at room temperature. The slides with the cells were incubated 
in a bath of KCM for 10 minutes, before incubating with the primary antibodies. The 
antibodies were diluted to the recommended concentration with KCM + 0.1% BSA. The 
slides were stored in a humidified chamber in the fridge for one hour. After incubation the 
slides were washed twice in a bath of KCM for 5 minutes. They were incubated with the 
secondary antibody (FITC-α-rabbit IgG and TRITC-α-mouse IgG) in a 1:50 dilution. They were 
stored in a humidified chamber in the fridge for another hour. The slides were washed again 
twice in a bath of KCM for 5 minutes. For fixing the cells the slides were incubated in a bath 
of 4 % formaldehyde/KCM for 10 minutes. Afterwards they were washed with dH2O. Finally, 
slides were mounted with 7.5 µl of a 1µg/ml DAPI in Vectorshield solution and ethanol 
washed coverslips and sealed. 
 
Antibody Source Dilution/ Animal 
α-Msk1 Abcam ab 82194 1:1000 / rabbit 
α-MLL1N Millipore 05-764 1:1000 / mouse 
FITC 2nd,  α-rabbit IgG Abcam ab6717 1:1000 / goat 
TRITC 2nd ,α-mouse IgG Dako R0270 1:1000  / goat 
Table 2.2: Antibodies used for immunoflouresence microscopy 
 
KCM: 120 mM KCl  
20 mM NaCl 
10 mM Tris/HCl pH 8 
0.5 mM EDTA 
0.1 % Triton X-100 
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2.3.4 Flow Cytometry Analysis  
Per Analysis 50,000 – 100,000 cells were collected by centrifugation (1200 rpm, 5 min). The 
supernatant was discarded and the cell pellet was resuspended in 3 ml of ice-cold PBS and 
centrifuged again at 1200 rpm for 5 min. The supernatant was discarded and the cell pellet 
resuspended in 1 ml of cold 80% Ethanol/PBS. The samples were stored overnight in the 
freezer. After the incubation cells were centrifuged (800 rpm, 10 min) and resuspended in 1 
ml ice-cold PBS. After another spin (800 rpm, 10 min) the cells were resuspended in 100 µl 
PBS per 5x104 cells. To this 20 µl propidium iodide (concentration 5 mg/ml) per ml PBS is 
added and incubated for 30 - 60 minutes.  The samples were then measured. 
 
2.3.5 Co- Immunoprecipitation 
Co-Immunoprecipitation was performed on LCL cells. 1x108 cells were collected and washed 
twice in ice-cold PBS, to which 5 mM sodium-butyrate was added. The final cell pellet was 
resuspended in 300 µl NP40 buffer with 150 mM NaCl. The mixture was vortexed and 
incubated on ice for 20 min for cell lysis. The lysate was centrifuged for 20 min at 13000 rpm 
and the supernatant was kept. In the meantime protein A sepharose, which was soaked 
overnight in NP40 buffer with 150 mM NaCl, was adjusted (50% sepharose and 50% NP40 
buffer with 150 mM NaCl). In order to clear the lysate the volume was made up to 400 µl 
with NP40 buffer with 150 mM NaCl and 40 µl of the adjusted sepharose beads were added. 
The mixture was incubated on a rotating wheel at 4⁰C for 30 minutes. The mixture was 
centrifuged (13000 rpm, 1 min) and the supernatant was kept. The lysate was incubated 
overnight with 20 µl of antibody at 4⁰C on a rotating wheel. Then 40 µl of adjusted 
sepharose was added and left for 3 hours at 4⁰C, before centrifuging for 3 minutes, at 3000 
rpm and 4⁰C. The supernatant is kept as sample S1. The beads were washed three times 
with NP40 buffer with 200 mM NaCl. The beads and the samples S1 were mixed with 
Laemmli-buffer and loaded on a gel and a western blot prepared afterwards.  
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Antibody Source Dilution/ Animal 
α-Msk1 Abcam ab82194 1:500 / rabbit 
α-NFκB 
α-MLL1N 
Abcam ab7970-1 
Millipore 05-764 
1:1000 / rabbit 
1:500 / mouse 
α-MLL1C Millipore 05-765 1:500 / mouse 
FITC 2nd,  α-rabbit IgG Abcam ab6717 1:1000 / goat 
TRITC 2nd ,α-mouse IgG Dako R0270 1:1000  / goat 
Table 2.3: Antibodies used for the Co-IP
PBS:  2.7 mM KCl 
137 mM NaCl 
8.1 mM Na2HPO4 
1.76 mM KH2PO4, pH 7.4 
 
NP40 buffer with 150 mM NaCl:   1% Nonidet P40 
10% Glycerol 
50 mM Tris (pH 7.5)   
   0.1% Sodium Azide 
150 mM NaCl 
 
NP40 buffer with 200 mM NaCl:   1% Nonidet P40 
10% Glycerol, 50 mM Tris (pH 7.5) 
          0.1% Sodium Azide 
200 mM NaCl  
 
Laemmli-buffer:  200 mM Tris (pH 6.8) 
 8% SDS 
40% Glycerol,  
      2.4 M β- mercaptoethanol 
Bromophenol blue 
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3. Results 
 
3.1 Does Msk1 contribute to regulation at MLL1 target genes? 
Msk1 (Mitogen- and Stress- activated Protein Kinase 1) is a protein kinase involved in the 
phosphorylation of H3S10 (Soloaga et al., 2003), but is also downstream of the MAP-kinase 
signalling pathway (Edmunds and Mahadevan, 2004; Huang et al., 2006). Previous data from 
the lab (not published) suggest that H3S10p contributes to Hoxa gene activation, for 
example an enrichment of H3K4me3, H3S10p and Msk1 was observed over the 
transcriptional start site of Hoxa4 and of Hoxa5 in HPC7 cells. This enrichment was absent in 
differentiated megakaryoctes, where these active genes are repressed. Furthermore the 
sites of Msk1 binding correlated with the modifications deposited by proteins of the MLL 
complex, though the positions of MLL1 and Msk1 deposited marks did not correlate. The 
data suggested that Msk1 is either part of the MLL complex or acted together with the MLL 
complex to regulate Hoxa gene expression. 
 
3.2 Knock-down of Msk1 in HPC-7 cells 
To examine the role of Msk1 on MLL1 target genes, Msk1 should be knocked down. The 
Nucleofector Kit by Lonza was used to transfect a vector coding for shRNAs in the cells using 
electroporation. This knock-down was only transient and therefore the optimal time-point 
for the knock-down, with the lowest Msk1 levels, needed to be identified. Therefore time-
courses were performed. For the first trial, samples were taken at 13, 16, 19 and 22 hours 
after transfection. As shown in Figure 3.1 A, RNA levels were at the lowest level after 13 
hours post-transfection, while after 19 hours no difference to the control could be 
observed. In a second experiment samples were taken at 10, 11, 12, 13 and 14 hours after 
transfection. It could be shown that the RNA levels at 12 hours were even lower. Under 
optimal conditions Msk1 RNA transcript levels could be reduced about ~90%.  
To reveal that the knock-down, had not only influences on the Msk1 RNA level of the cells, 
but also on the protein level, transfected cells were collected at 12 hours post-transfection 
and prepared for immuno-flourescence microscopy. The collected cells were directly 
centrifuged onto slides and fixed in formaldehyde. After the last sample was collected the 
cells were stained with α-Msk1 antibody and detected with a 2nd FITC-antibody (Figure 3.1 
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B). As control HPC-7 cells, transfected with a GFP expression vector, are presented. Msk1 
showed a distribution throughout the nucleus, but show a punctate distribution, termed 
“speckles”. In comparison to this control cells the Msk1-signal in the cells, transfected with 
Msk1 Knock-down vector, was reduced. 
During the transfection the majority of the cells died. In order to enhance the survival of the 
cells, twice as much SCF (Stem Cell Factor) was added to the HPC7 Growth Medium. As a 
result clearly more cells survived. However, as a negative effect, the efficency of the knock-
down dropped. This was apparent when the effect of the knock-down was examined. The 
original data sowed a >90% kockdown at transcript level (Fig 3.1 A) but using this „enhanced 
recovery“ RNA transcript levels were reduced by 50% (Fig 3.2 B).  
However, the final question was to examine if the down-regulation of Msk1 has any impact 
on MLL1 target genes. Therefore a qPCR with primers covering HoxA6 and Meis1 genes was 
performed. Those target genes were chosen, because they are known target of MLL1. 
Although the Msk1 knock-down was poor in quality, still a down-regulation of HoxA6 (-27%) 
and Meis1 (-23%) could be observed (Figure 3.1 B).   
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Figure 3.1: Knock-down of Msk1 in HPC7 cells. (A) Cells were transfected and collected at indicated time-
points. The qPCR was performed after collecting the last sample. For a positive control cells were transfected 
with GFP, the RNA levels were normalized to Actin.  It could be shown, that after 12 hours the maximum of the 
knock-down was reached. (B) To confirm the RNA findings, immuno-staining of transfected HPC7 was 
performed. The reduction of Msk1 could be observed at the protein level, too.   
 
 
Figure 3.1: Knock-down of Msk1 in HPC7 – time course of RNA-levels 
GFP 
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Figure 3.2: Knock-down of Msk1 in HPC7. (A) Cells were transfected with either a GFP control vector or the 
Msk1 Knock-down vector and collected 12 hours after transfection. A whole cell extract of the samples were 
prepared and a western blot was performed. The membrane was probed with an antibody against Actin, which 
showed equal sample loading.  The Msk1 antibody a  ~35% decreased abundancy of the Msk1 protein. (B) A 
qPCR was performed 12 hours after transfection. For a positive control cells were transfected with GFP, the 
RNA levels were normalized to Actin levels. The Knock-down efficency was, with a reduction of only 50% of 
Msk1 RNA, poor. However, this was enough to show a down regulation of HoxA6 and Meis1 RNA, which  are 
known targets of MLL1, of ~25 %. 
 
Figure 3.2: Knock-down of Msk1 in HPC7 
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3.3 Interaction of MLL1 and Msk1 
To adress the question if there is also a physical interaction or if chromatin may „bridge“ 
interaction (Figure 3.3 A, right panel), Co-Immunoprecipitation in LCL cells was performed. 
First a pull-down with MLL1 was performed and probed with Msk1. As a positive control a 
pull-down with NFκB was performed as well, because NFκB is known to interact strongly 
with Msk1 (Figure 3.3 A, left). Shown are the supernatants (S1), as well as the beads of the 
pull downs,  that were probed with an antibody against Msk1 (Figure 3.3 B left). In  both 
pull-downs a clear band of the right size of ~90 kDa (indicated by an arrow) could be 
detected, that was absent in the supernatants. This gives a hint for a interaction of MLL1 
and Msk1. Obviously there is a very prominent band of  smaller size, that appears as a smear 
in the NFκB pull-down (indicated by a star), likely to be IgG heavy chain (~55 kDa).  
Msk1 and MLL1 are both acting on histone H3. To determine if histone H3 is involved in the 
interaction of MLL1 and Msk1, the membrane was reprobed with an antibody against the 
tail of histone H3.  As shown in Figure 3.3 B on the left, a signal can be found in all samples, 
even in the pull-down with NFκB, which is not known to interact  with histones. Therefore it 
needs further investigation and methods to answer the question, if chromatin may bridge 
the interaction.  
To control the findings of the Co-IP, the procedure was reversed (Figure 3.3 B, right). A pull-
down with Msk1 was performed and the western probed for MLL1. As MLL1 is very large 
(full-length 430 kDa), a lower concentrated gel of  10% was run. Because MLL1 consiststs of 
two fragments (N-terminal ~300 kDa, C-terminal ~180 kDa) the western was probed for 
these two individual fragments. Unfortunately no MLL1 fragment could be detected, even in 
the supernatants. This indicates the antibody is unlikely to be adequate for the experiment. 
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Figure 3.3: Co-IP of MLL1 and Msk1. (A) Representation of the Co-IP experiments. Right panel: It is known that 
Msk1 and NFkB are binding, so the IP with it was used as a positive control. It should be examined, if MLL1 and 
Msk1 are interacting and therefore can be pulled down together. Left panel: Two theories are possible. Either 
MLL1 and Msk1 interact directly with each other (top) or they work on the same site of histone H3 (bottom). 
(B) Left panel: A Co-IP for MLL1 and NFκB, as a positive binding control, was performed. The supernatant (S1) 
and the beads were loaded and probed with Msk1 antibody (top) and later reprobed with Histone H3 tail 
antibody (bottom). Right panel: A Co-IP for Msk1 was performed and the supernatant (S1) and the beads were 
loaded. The membrane was probed with antibodies against the N- and the C-terminal of MLL1. 
 
Figure 3.3: Co-IP of MLL1 and Msk1 
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3.4 Immunofluorescence microscopy of Msk1 and MLL1 
 To see if in the cell Msk1 and MLL1 are in close proximity, a localisation study on either LCL  
cells or HPC7 cells was performed. The cells were centrifuged on slides and stained with an 
antibody against Msk1, which was detected by a 2ndFITC-conjugated anti rabbit IgG 
antibody, and with an antibody against MLL 1, which was detected by a 2ndTRITC-conjugated 
anti mouse IgG antibody. In both cell types Msk1 and MLL1 showed the same distribution, 
whereas Msk1 tended to form „speckles“ and MLL1 not. However, the staining was not 
equal in all cells. On some cells an overall staining could be observed, on others it was more 
punctate and on others there was a disconnection of Msk1 and MLL1. The latter was 
especially observed on cells in which the mitotic chromosomes were visible. This lead to the 
hypothesis, that the localisation of the proteins differ during the cell cycle.  
To examine if these differences in staining are cell cycle dependent the cells were either 
treated with Thymidine or Colcemid. Both substances arrest the cells in the cell cycle at 
specific time points (Figure 3.4 A). Thymidine blocks the cell during the S-phase, so that as a 
result the cell population is enriched with cells in G1/S-phase. Colcemid inhibits the 
formation of the mitotic spindle, which leads  to a cell population with cells in G2-phase or  
mitosis. To control the effect of Thymidine and Colcemid a flow-cytometric analysis was 
performed (Figure 3.4 B).Propidium Iodide staining was used as a measure of nuclear DNA 
content (i.e. n-number). In the left diagram a unsyncronised cell population was measured 
and a typical cell cycle diagram with two peaks (one for G0/G1 and one for G2/M) were 
obtained. In the middle diagram a Thymidine treated population was analysed. As expected 
only the first peak (G0/G1) was obtained. In the right diagram a population treated with 
Colcemid was examined and the second peak (G2/M) was observed. However the block was 
not perfect and as G0/G1-phase shoulder demonstrated.  
The further colocalisation study was then repeated with one of the two different subfraction 
of arrested cells (Figure 3.5 A-D). In A and C an equal, all-over staining of the cells with both, 
Msk1 and MLL1 antibody, dominated. In B and D cells, which were in mitosis, were shown. 
In those cells Msk1 and MLL1 seemed to disconnect from the DNA (stained with DAPI) and 
tend to form more „speckles“ (B) or to be packed in structures outside the nucleus (D).  
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Figure 3.4: Cells arrested in the cell cycle. (A) In order to examine the behaviour of Msk1 during the cell cycle, 
LCL cells were either treated with Colcemid, which inhibits the cells in mitosis, or with thymidine, which 
inhibits the cells in the S-Phase. (B) To control the effects of Colcemid and Thymidin a Flow cytromety analysis 
was performed, using propididum iodide incorp to assess nuclear content (n number). 
 
 
 
Figure 3.4: Cells arrested in the cell cycle 
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Figure 3.5: MLL1 and Msk1  Immuno-Staining  
(A) LCL cells treated with Thymidine  
(B) LCL cells treated with Colcemid  
(C) HPC7 cells treated with Thymidine 
(D) HPC7 cells treated with Colcemid.                                 Green=Msk1, Red=MLL1, Blue=DAPI 
 
Figure 3.5: MLL 1 and Msk1 Immuno-Staining 
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3.5 Msk1 during the cell cycle 
The  observation, that apparently in some parts of the cell cycle less protein is (i. e. Fig 3.5 
BD) and that Msk1 and MLL1 are distributed differently throughout the cell cycle lead to the 
question if the total amount of these proteins differed, too. To answer this question equal 
volumes of LCL cells were either treated with Thymidine or Colcemid to obtain G2/Mitosis  
and G1/S population. For comparison the same volume of untreated LCL cells were taken. 
After incubation whole cell lysis extracts were prepared and then 200 µl of cell extract were 
loaded on a gel. A Western Blot was performed and the membrane was first incubated with 
an antibody against Msk1 and for a loading control with an antibody against Actin. A 
representative Western Blot is shown in Figure 3.6 A. As the actin control revealed there 
was more Actin present in the untreated cell population, than in the treated ones, with the 
lowest Actin levels seen in the Colcemid treated cell population. However an enrichment of 
Msk1 in the Thymidine treated cell population could be observed.  
The experiment was repeated twice and the results are shown in figure 3.6 B. Depending on 
the total abundancy of protein and quality of the antibodies, the Actin signal was much 
stronger than the Msk1 signals.  As indicated in the blot (Figure 3.6 B, upper panel), the 
loading differed between the different experiments. By normalising for this loading artefact, 
differences in the strength of the Msk1 signals could be observed (Figure 3.6 B, lower 
panel). Taking this and the observation of the Actin loading control into consideration, it can 
be said, that in the unsyncronised population as well as in the Colcemid treated one the 
abundancy of Msk1 is more or less the same.  A small enrichment in the Thymidin treated 
population could be observed. Taken together it can be determined, that although the Msk1 
distribution changes in the different cell cycle stages, the total amount of protein is roughly 
the same, with maybe a slight enrichment in G1/S-phase. 
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Figure 3.6: Msk1 during the cell cycle. (A) Western Blot. LCL cells were treated with either Thymidine or 
Colcimid to arrest them during the cell cycle. As a control unsynchronised cells are shown as well. First the 
membrane was incubated with α-Msk1 Antibody and to control the loading then with β-Actin antibody. (B) 
Quantification. Three individual experiments were performed. Signals were quantified using arbitary units. 
Figure 3.6: Msk1 abundance during the cell cycle 
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4. Discussion 
 
MLL1 is the human homologue of Drosophila’s  trithorax  (TRX), a group of transcriptional 
regulators that positively maintain expression of homeobox (HOX) transcription factor 
genes, which play an important role in the expansion of the progenitor cells of the myeloid 
line in haematopoesis (Milne 2002, Slany 2005). However less is known about how MLL is 
regulated. Results from the lab (data not published) suggested that Msk1 (mitogen- and 
stress-activated protein kinase 1) may play a part in it. Msk1 is phosphorylated and 
activated by the mitogen-activated proteinkinase (MAPK) pathways and was identified as a 
H3 kinase (Dyson 2005). The MAPK pathways regulate eukaryotic gene expression in 
response to extracellular stimuli (Edmunds 2004). In the lab (data not published) it could 
also been shown, that H3S10p contributes to Hoxa gene activation, for example an 
enrichment of H3K4me3, H3S10p and Msk1 was observed over the TSS of Hoxa4 and of 
Hoxa5 in undifferentiated HPC7 cells. This enrichment was absent when these genes are 
active in differentiated megakaryocytes, where the genes are repressed. Here I have 
examined if Msk1 takes part in the regulation of MLL1 target genes and how it might be 
involved with the MLL1 complex.  
 
4.1 Does Msk1 take part in the regulation of MLL1? 
To examine the role of Msk1 in the regulation of MLL1 a knock-down of this protein in HPC7 
cells was established. Under good conditions a decrease of 90% of the RNA could be 
generated, after 12 hours of incubation, which resulted in a strong Msk1 protein decrease. 
However, the harvest was poor, as the majority of the cells died. In order to enhance the 
survival of cells, twice the amount of SCF was added to the recovery media, with the result, 
that more cells survived but the knock-down efficiency dropped. Under normal conditions 
those cells were probably seriously damaged instead of transfected and would have died. As 
the samples of the transfected cells were so precious, further experiments were carried out 
with the material, which was less efficiently transfected. qPCR revealed that only ~50% RNA 
transcript reduction could be obtained under these conditions. Nevertheless it led to a 
decrease of the total amount of Msk1 protein of ~35%. It could be demonstrated that this 
was enough to down-regulate the RNA appearance of two known MLL1 target genes, HoxA6 
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and Meis1, down nearly a quarter.  This is a strong indication for the regulatory involvement 
of Msk1 on MLL1 target genes. Still, there are questions to answer. It is not yet shown, that 
the down-regulation of Msk1 also significantly effects the level of HoxA6 and Meis1 
proteins, are the acting components in a cell. It also has to be proved, if the regulation of 
MLL1 target genes by Msk1 is a general effect on MLL1 target genes and if yes, what it 
means for the fate of the cells.  
It also should be examined if a physical interaction between those two proteins exists 
(Figure 4.1). Therefore Co-Immunoprecipitation were performed. When a pull down with 
MLL1 was carried out and probed with an antibody against Msk1 a signal of 90 kDa could be 
detected. This argues for a interaction of Msk1 and MLL1. In the reverse experiment, 
however, this interaction could not be demonstrated. This is probably due to the 
experimental procedure, this was an initial trial and maybe with other antibodies and/or 
refined procedure the interaction can be demonstrated, too. First of all the MLL 1 
antibodies need to be tested for immuno-detection on a membrane. So far the antibodies 
have been established and used for immuno-staining. Second, MLL1 is a very big protein, 
which needs to be run on a lower percentage SDS-gel and longer in blotting. Third and 
finally, it seems that protein degradation is a problem and this may reduce detection. Using 
Co-IP, the hypothesis, that Msk1 and MLL1 interact via chromatin and/or histone H3, which 
therefore acts as a “bridge” (Figure 4.1), should be tested. Unfortunately histone H3 could 
be detected in all samples and in the control pull-down with NFκB, which does not interact 
with histone H3, so no statement can be made. This is probably due to the procedure, as 
histones are known to bind non-specifically to beads.  
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stimuli 
Figure 4.1: Hypothesis of the Regulation of MLL1 by Msk1  
1 
2 
Figure 4.1: Hypothesis of the Regulation of MLL1 by Msk1. There are indications, which suggest that MLL1 is 
regulated by Msk1. So far two model hypothesis are plausible. First (1) Msk1 and MLL1 directly interact with 
each other or second (2) Msk1 and MLL1 interact indirectly via chromatin.   
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4.2 How is Msk1 involved with the MLL1 complex? 
To investigate how Msk1 and MLL1 interact with each other, a co-localisation study was 
carried out. Cells were fixed on slides and stained with antibodies for Msk1 and MLL1. Msk1 
and MLL1 showed nucleus specific, over all staining. As both proteins act on chromatin, this 
was not a surprise. But as they showed no specific pattern it is impossible to say if they are 
co-localised or if they just happened to be at similar locations as they are acting on 
similar/same sites. Although no statement about the co-localisation could be made, it 
attracted attention, that the staining was not similar in all cells. Most cells were stained 
throughout the nucleus, but some cells showed a speckled, punctated staining, especially 
for Msk1 and on some cells the staining seemed to be separated from the chromatin. The 
latter was mostly the case when also the mitotic chromosomes were visible. This led to the 
hypothesis, that the distribution of Msk1 and MLL1 varied during the cell cycle. To test this 
theory cells should be blocked (i.e. with thymidine) and released  to synchronise the cell 
population through the cell cycle and samples of every stage of the cell cycle could then be 
taken. It was found that the cells could be trapped in the G1 phase, but after the thymidine 
was washed out the cells refused to procced further through the cell cycle. The same could 
was observed when the cells were serum-starved and accumulated in G1 phase.  
To examine cell-cycle phase dependency, two subpopulations were created by arresting 
cells with thymidine (G1/S phase) and with colcemid (G2/Mitosis). Although the arrest 
generated by these agents was not perfect (i.e. in the G2/Mitosis population a lot of G0/G1 
phase cells were detected), an enrichment could be well observed. In the G1/S phase 
population the majority of cells showed an all-over nuclear staining. During mitosis, which 
was easy to identify because of it metaphase chromosomes, Msk1 and MLL1 was evicted 
from the chromatin and were stored in speckles or vacuoles. Nevertheless in the G2/mitosis 
population the other cells were either stained over all or speckley, but it was not possible to 
say in which stage of the cell cycle they were exactly.  
Having observed, that the connection of Msk1 and MLL1 differs in the two populations the 
question arose if the total content of protein differed. To answer this question whole cell 
lysis extracts were prepared and a western blot performed or the two populations. A slight 
enrichment of Msk1 in the G1/S phase population could be observed, but this was 
preliminary data, where the loading control β-actin was varying a lot and measurements 
between the three experiments varied a lot, too. One problem obviously was that the same 
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volume of cell culture was prepared for treatment with thymidine and colcemid as well as 
taken for control. However no cells were counted, which may have resulted in different 
amounts of cells in the different experiments. Thymidine and Colcemid may have cell toxic 
effects and decreased the numbers in the treated cell populations. When repeating this 
experiment it should be ensured, that the same numbers  of cells are taken when preparing 
whole cell extracts. The other thing to think about is, if actin is a good loading control or if 
its content may vary in the cell cycle naturally too. To rule possible fluctuations of the 
loading control out, it would be better to use histone H3 as a loading control.  The amount 
of histone H3 is stable through the cell cycle and the C-terminal antibody is not subject to by 
any modifications, which would lead to artefacts.  
The biggest disadvantage is, that the division into those two populations only mimics cell 
cycle distribution. As it was not possible to synchronise and release the cells again, the other 
option is to sort cell by FACS. This would yield distinct sets of cells and a discrimination 
between the cells in G1-, S- and G2-phase would be possible 
 
4.3 Concluding remark 
In this study, it could be demonstrated that Msk1 does have a regulatory effect on MLL1. 
However the methods need to be refined as discussed above and further investigation are 
needed to determine how, or whether Msk and MLL complex interact, what the general 
consequence of the regulation is, and if Msk1 could be used as target for leukaemia 
treatment.  
It was also demonstrated that Msk1 and MLL1 both seem to follow a cell-cycle dependent 
distribution, and it can be speculated that the total amount of protein may vary slightly. 
Further investigations need to be done to make these data conclusive and to address the 
questions if this has an impact on how MLL-deposited marks during the cell cycle are 
retained.  
Taken together, a link between two cellular key processes could be provided. Epigenetic 
gene activation by MLL1 was connected to the response to extracellular stimuli by Msk1 as a 
down-stream target of the MAPK pathway.  This is consistent with the described role of 
Msk1 as a remodeller of chromatin on immediate early genes by histone H3 
phosphorylation (Drobic, Perez-Cadahia et al. 2010). The findings of the project suggest that 
Msk1 may act on multiple MLL1 target sites. The finding that Msk1 acts on trithorax 
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mediated processes via MLL1 is backed-up by the finding that Msk1 mediates epigenetic 
changes during embryonic stem cell differentiation (Lee, McCool et al. 2006) and that Msk1 
is able to reverse polycomb complex induced silencing (Gehani, Agrawal-Singh et al. 2010; 
Lau and Cheung 2011). Resulting from the fact, that there are several human MLL methyl-
transferases and two Msk isoforms with different distinct function it would be interesting to 
examine if there is a whole new complex network of interactions. 
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Abstract 
Limited neuronal regeneration following CNS injury is due to interactions between the 
myelin derived inhibitors and the Nogo-receptor (NgR) ternary complex, consisting of NgR, 
p75 and Lingo1. The inhibitory role of Lingo-1 presents a novel target for nerve repair and 
remyelination therapies. Lingo1 is one member of a large group of CNS enriched membrane 
proteins, with a LRR and an Ig domain in their ectodomain. Recently, other members of the 
LRR-Ig protein family, namely Amigo-proteins, have been reported in the context of 
neuronal development, survival and regeneration. This study has combined biochemical, 
binding and structural approaches to further characterise the function of Amigo proteins, 
with a particular emphasis on whether Amigo proteins can substitute for Lingo1 in forming a 
ternary NgR complex. The ectodomains of Amigo1 and Amigo3 were expressed and 
successfully purified by Ni-NTA affinity and gel filtration chromatography. Based on BIAcore 
binding analyses, whereas Amigo 1 and Amigo 3 demonstrated no binding with p75, weak 
interactions were found with NgR. In addition, initial cross-linking experiments with BS3 
indicated, that Amigo1, but not Amigo 3, can self-associate forming dimers in solution. 
Finally, crystallisation trials for Amigo1 ectodomain identified a condition that yielded 
suitable sized crystals for preliminary X-ray diffraction experiments.  
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1. Introduction 
 
1.1 The central nervous system 
The mammalian central nervous system (CNS) consists of more than 20 billion neurons, 
which are connected by trillions of synapses. The formation of synapses, called 
synaptogenesis, is a complex process, including axon path-finding, target recognition and 
the elaboration of the synaptic contact. To ensure that functional neuronal circuits are 
specifically installed, guidance mechanisms have evolved to regulate the growth and 
connection of neurons in the developing brain (Benson, Colman et al. 2001). Synaptogenesis 
is a process that is not limited to the development of the CNS, as the CNS requires constant 
refinement, with modification and elimination of old synapses and generation of new ones 
in response to aging, learning and damage (Yiu and He 2006). CNS injury can disrupt this 
process leading to neuronal death, axon degeneration and demyelination. Following a CNS 
injury a glial scar is formed within days around the injury site and forming a physical barrier 
for axonal sprouting. Furthermore, scar-associated molecules function as chemical inhibitors 
that block axon regeneration generating an additional barrier for axon regeneration (Giger, 
Hollis et al. 2010). Damage of CNS myelin further attenuates axonal growth through the 
action of myelin derived degradation products. These have been characterised in the last 
decade and include Nogo, myelin-associated glycoprotein (MAG) and oligodendrocyte-
myelin glycoprotein (OMgp), all of which bind to the Nogo Receptor (NgR) (Yamashita, 
Fujitani et al. 2005). The NgR receptor is a trans-membrane protein with multiple Leucine-
rich repeats (LRRs) in its ectodomain (He, Bazan et al. 2003). 
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1.2 LRR domains and the LRR superfamily 
The LRR domain is important for facilitating protein-protein interactions and is found in 
bacteria, fungi, plant and animals. The LRR motif is generally rich in hydrophobic residues, 
preferentially leucines and are generally 20-29 residues long containing a characteristic 
conserved 11 residue sequence motif (LxxLxLxxNxL where x=amino acid, L=leucine and 
N=asparagine (Kobe and Kajava 2001). Other hydrophobic residues (phenylalanine, 
Isoleucine or valine) can substitute for the leucine and asparagine residues. Proteins with 
LRR architecture usually form curved solenoid structures, in which each turn consists of one 
repeat, with hydrophobic residues packed into the inner core of the solenoid providing 
protein stability. In addition, the LRRs are usually flanked by caps, which protect the 
hydrophobic residues of the first and the last LRR module (Bella, Hindle et al. 2008).   
The LRR motif is highly conserved and present in a variety of proteins with diverse functions 
ranging from innate immunity regulation through Toll-like receptors (Schuster and Nelson 
2000) to neural development, neurite outgrowth and synapse formation (de Wit, Hong et al. 
2010). Proteins with LRR motifs often possess other characteristic modules such as Ig and 
fibronectin domains and the large LRR superfamily can therefore be divided into subgroups 
based on their architecture, including  the LRR (LRR domain only), LRR-Ig (LRR + Ig domain) 
and the LRR-Toll (LRR + Toll/Interleukin-1 receptor domain) groups (Kobe and Kajava 2001).  
 
1.3 The Nogo-Receptor Complex 
During the search for binding partners of Nogo, a glycosylphosphatidylinositol (GPI) linked 
protein with multiple LRRs in its ectodomain was identified as a receptor that mediates 
inhibitory signals to axonal outgrowth. This newly identified protein was termed the Nogo 
Receptor (NgR) and binding of Nogo led to collapse of axonal growth cones (Fournier, 
GrandPre et al. 2001). The ligand binding domain of the NgR is comprised of nine LRRs, 
which are flanked by two cysteine-rich capping modules, that form a solenoid structure (He, 
Bazan et al. 2003). The NgR shows the typical LRR motif sequence 
(xLxxLxxLxLxxNxLxxLPxxFx), in which the leucine is often replaced by phenylalanine. The 
concave surface of the NgR is enriched in aromatic residues, which form two patches that 
are separated by a group of charged residues that shape the ligand binding site. A second 
more discrete binding site is located at the C-terminal end of the ectodomain, formed by 
LRRs at the C-terminal end and the bulkier C-terminal flanking cap and offers a recognition 
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site for accessory signalling receptors, which are necessary for signal transduction since NgR 
as a GPI linked protein cannot signal independently (He, Bazan et al. 2003). NgR has been 
shown to bind to two co-receptors, namely p75NTR and Lingo-1 and together they form a 
functional ternary complex (Figure 1.1) (Mi, Lee et al. 2004).    
p75NTR is a type I transmembrane protein and member of the neutrophin family of growth 
factors which mediates intracellular signalling by activating the RhoA-pathway (Wang, Kim 
et al. 2002). Rho molecules are membrane linked GTPases, which activities are controlled 
internally by Guanine nucleotide exchange factors and are involved in cytoskeletal 
organization (Schmidt and Hall 2002). Interestingly, p75NTR is highly expressed in the 
developing nervous system but decreases during the postnatal period and adulthood. In the 
adult brain only a subpopulation of mature neurons express p75NTR.  Previous studies have 
highlighted that TROY, a member of the TNF receptor family, can substitute for p75NTR 
function (Park, Yiu et al. 2005). 
The second co-receptor, Lingo-1, is exclusively expressed in the CNS. The ectodomain of 
Lingo-1 is made up of two distinct modules a LRR and an Immunoglobulin (Ig)-like domain. 
The Lingo family contains three variants (Lingos 2-4), which are highly conserved (44% - 61% 
amino acid sequence identity between the Lingo paralogues and 99% sequence identity 
between mouse and human orthologues) (Mi, Sandrock et al. 2008).  
Collectively, the components of the NgR Complex provide ligand binding (via NgR), facilitate 
signalling (via p75NTR) and promote stability (via Lingo-1). Since Lingo-1 is restricted to neural 
tissues and has a critical role in transmitting inhibitory signals within the CNS via the NgR 
complex, it represents an attractive candidate for therapeutic targeting to improve recovery 
following CNS injury.  
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Figure 1.1: The Nogo-receptor complex 
Figure 2.1:  The Nogo-receptor complex.  
Figure 1.1: The Nogo-receptor complex. The Nogo-receptor complex consists of the NgR, p75NTR and 
Lingo-1. Troy can substitute for p75NTR function by forming a ternary complex with Lingo-1 and NgR 
(left side).  Ligands of the NgR complex include the myelin derived proteins OMgp, MAG and Nogo. Their 
binding activates the NgR complex, which binds to the Rho guanine dissociation inhibitor (RhoGDI). This 
leads to the activation of Rho-GDP by guanine nucleotide exchange factor (GEF) and into the collapse of 
the growth cones in axons and the inhibition of neuronal outgrowth. (McDonald, Bandtlow, Reindl, 
2011) 
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1.4 Lingo-1 
Lingo-1 is a type I transmembrane protein with an ectodomain composed of 12 LRR, which 
are folded in the typical solenoid structure and flanked by N- and C-terminal caps. It is 
closely followed by an Ig-domain, which related in nearly a 90⁰ angle to the last LRR. The Ig 
module is connected to the transmembrane and cytoplasmic tail regions by a stalk (Figure 
1.2 A). Lingo-1 forms a ring like tetramer structure that leads to clustering of charged 
patches on the inner and outer rims of the ring (Figure 1.2 B), which may facilitate the 
binding of multimeric signalling complexes on the cell surface. This is in accordance with the 
putative role of Lingo-1 as an adapter for co-receptors. Although the Ig domain does not 
facilitate tetramer formation, it  suggests it plays a role in co-receptor recognition (Mosyak, 
Wood et al. 2006).  
Expression analyses of the NgR components NgR1, p75NTR and Lingo-1 revealed only a small 
time-frame for parallel expression, occurring during the late postnatal stages. (Mi, Miller et 
al. 2005). Furthermore, Lingo-1 is expressed in several brain regions lacking NgR1 or p75NTR 
expression, which indicates that Lingo-1 may participate in signalling events that are 
independent of the NgR complex (Llorens, Gil et al. 2008). Additional functions may include 
effects on neuronal survival via down-regulation of EGFR (Mi, Sandrock et al. 2008) and 
regulation of oligodendrocyte differentiation and myelination via NGF by interacting with 
the Lingo-1/TrkA receptor complex (Figure 1.2 C) (Lee, Yang et al. 2007). Also, Lingo-1 has 
been determined to be a negative regulator of oligodendrocyte differentiation and 
myelination, as the loss of Lingo-1 function increases branching and myelination (Mi, Miller 
et al. 2005, Zhao, Jin et al. 2007). It remains to be seen whether other members of the LRR-
Ig family have analogous functions to Lingo-1. 
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Figure 1.2: Structure and Function of Lingo1 
Figure 1.2: Structure and function of Lingo-1. (A) Schematic domain structure of Lingo-1 showing 
the N-terminal LRR-domain (red), the C-terminal Ig domain  (green), the stalk region (grey) and the 
transmembrane/cytoplasmic domain (blue). (B) Four Lingo-1 molecules form a ring like structure 
(left side, LRR and Ig domain are indicated). Electrostatic surface potential for Lingo-1 tetramer 
highlights the highly positive charged surface surrounding the inner ring structure (right side, view 
of the top surface; blue=positive and red=negative charge). (C) Lingo-1 participates in several 
signalling pathways. It is member of the NgR complex controlling axon regeneration (left) and is 
activated by the NGF/TrkA receptor complex to control oligodendrocyte differentiation and 
myelination (middle). Lingo-1 also interacts with EGFR and influences the Akt signalling pathway 
(right) (Mosyak et al. 2006 and Mi, Sandrock, Miller 2008). 
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1.5 The LRRIg family and the Amigos 
The LRRIg family has multiple related genes with a common structure consisting of a 
variable frequency of LRRs, which are typically flanked by an N-and C-terminal caps, closely 
followed by a single Ig-domain (Figure 1.3). The LRRIg family also includes the Amigo-
proteins, which share approximately 12-30 % sequence identity with the Lingo family (Figure 
1.4) (Kobe and Kajava 2001; Chen, Aulia et al. 2006) 
The Amigos were discovered in a screen for effectors of amphoterin, a heparin-binding 
protein that promotes neurite outgrowth and is enriched in the growth cones of neural 
cells. One transcript was predominantly up-regulated and therefore called amphoterin-
induced gene and ORF (Amigo). Based on sequence homology two related proteins (Amigo 2 
and Amigo 3) were identified.  The Amigos are type I transmembrane proteins, with a signal 
sequence for secretion and a transmembrane sequence. The extracellular region of all 
Amigos encompasses six LRRs, a cysteine rich N- and C-terminal cap as well as an Ig domain 
(Kuja-Panula, Kiiltomaki et al. 2003). It is a highly conserved protein; mouse and rat exhibit 
95% sequence homology whereas mouse and human show 89 % sequence identity.  Also, 
Amigos 1, 2 and 3 share ~50% sequence identity. Additionally the Amigo proteins show 
about 12 – 30 % sequence homology to Lingo1 although they have six LRRs less than Lingo1 
(Figure 1.4). Notably, the expression patterns of Amigos show a great variation. Amigo1 is 
primarily expressed in nervous tissue, whereas Amigo2 is mainly found in the cerebellum, 
retina, liver and lungs. In contrast, expression levels for Amigo 3 are more widespread (Kuja-
Panula, Kiiltomaki et al. 2003).  
In a second independent study the Amigo family was discovered in a different context. 
Amigo2 was discovered as a protein that was involved in depolarization and NMDA-
dependent survival of cerebellar granule neurons and was named Alvin. Overexpression of 
Alvin led to inhibition of KCl induced apoptosis (Ono, Sekino-Suzuki et al. 2003). 
At present, very little is known about the function of Amigo family members, particularly in 
relation to axon regeneration and myelination. 
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Figure 1.3: Members of the LRR-Ig family 
Figure 1.3: Members of the LRR-Ig family. Members possess tandem LRR domains followed by an 
Ig module within their ectodomains. Note that NLRR-3 and PAL contain an additional fibronectin 
type III repeat (Mi, Aulia, Li, Tang 2006). 
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Figure 1.4: Sequence comparison of Lingo1 and the members of the Amigo family. (shown are human protein 
sequences). The Amigo proteins show the same protein architecture like Lingo1. Their ectodomains contain a 
LRR domain, which is flanked by a N- and a C-terminal cap, as well as a Ig domain. The biggest difference is that 
Lingo1 contains 12 Leucine rich repeats, while the Amigo proteins contain only 6. Nevertheless 12 % of their 
sequences are highly conserved (red letters) and another 20 % are modestly conserved (blue letters). 
 
 
 
 
 
 
 
Figure 1.4: Sequence comparison of Lingo1 and the members of the Amigo family 
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1.6 Therapeutic relevance of the LRRIg family 
One of the key features following a CNS injury is that limited recovery is often observed. 
This is due to the physical and molecular factors of the glial scar in conjunction with the 
growth inhibitory environment. In this context proteins, which are responsible for the 
inhibition of nerve outgrowth, are potential therapeutic targets. Lingo-1 is a particularly 
attractive candidate because of its restricted expression in the CNS (McDonald, Bandtlow et 
al. 2011). More recently, soluble Lingo-1-Fc (ectodomain of Lingo-1 coupled to Fc region, 
serves as an antagonist for the NgR complex signalling pathway by competing with 
endogenous Lingo-1) was used in a rodent spinal cord injury model demonstrating 
promotion of axonal sprouting and increased oligodendrocyte and neuronal survival (Ji, Li et 
al. 2006). Lingo-1 may also play a significant role in Parkinson’s disease as its expression 
levels are elevated in the substantia nigra of patients with this disease. In a rodent model of 
Parkinson’s disease, the administration of Lingo-1-Fc led to enhanced neurite outgrowth 
and showed neuro-protective effects (Inoue, Lin et al. 2007).  
Therapy with anti-Lingo-1 antibodies that antagonize the effect of endogenous Lingo-1 have 
also been of interest. As Lingo-1 modulates the differentiation of oligodendrocyte precursor 
cells (OPC), one possibility is that anti-Lingo-1 antibodies could promote OPC differentiation 
and myelination and therefore offer a potentially novel strategy for the treatment of 
multiple sclerosis (MS) (Mi, Miller et al. 2009).  
Despite these findings it still remains unknown whether Lingo-1 is the most functionally 
relevant member of the LRR-Ig family as a component of the Nogo-receptor complex and 
therefore a critical player in the inhibition of neuronal differentiation. 
 
1.7 Aims 
Recent Microarray experiments comparing injured CNS tissue to non-injured CNS tissue, 
showed up-regulation of Amigo proteins, whereas Lingo-1 levels remained unchanged after 
injury. This suggests, that the Amigo proteins (particularly Amigo3) could be functionally 
relevant in CNS regeneration. In addition, subsequent co-immunoprecipitation experiments 
found that the Amigo proteins could be co-purified with NgR and p75NTR, suggesting that the 
Amigo-proteins may substitute for Lingo-1 in forming a ternary NgR complex (Lab M. 
Douglas, unpublished data). For Lingo-1 a direct binding of its ectodomain to NgR and p75 
could be demonstrated (Mosyak, Wood et al. 2006). It is possible that  Amigo proteins could 
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bind to the NgR and p75 similar to Lingo1, forming  a more efficient Nogo-receptor-complex 
for activation. In order to formally test this hypothesis soluble His-tagged ectodomains of 
the Amigo family (Amigos 1 - 3) will be over-expressed using insect cell expression systems 
and purified with Ni-NTA and size exclusion chromatography. Purified soluble Amigo 
ectodomains will be utilised for biochemical and biophysical analyses including cross-linking 
experiments, BIAcore protein-protein binding analysis and structural studies. Collectively, 
these experiments will go towards gaining a greater understanding of the role of Amigos in 
forming NgR complexes and in verifying whether Amigos are suitable therapeutic targets 
following CNS injury.     
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2. Materials and Methods 
 
2.1 Cell culture 
 
2.1.1 Cultivation of S2 cells 
Protein expression vectors encoding the proteins of interest were co-transfected into the 
Drosophila cell line S2 alongside a separate vector conferring Hygromycin B resistance. The 
cells were grown in a selecting medium consisting of “complete growth medium” 
supplemented with 0.03% Hygromycin B. Cells were transferred into fresh medium, 
containing 10% conditioned medium, every 5 days. Small volumes of culture (15-20 ml) 
were seeded at a density of 1x106cells/ml into T-75 flasks and incubated at 27⁰C in a non-
humidified incubator, allowing the cells to grow semi-adherently. Larger volumes (>125 ml) 
were seeded at a density of 1.2x106cells/ml and grown in 500ml Erlenmeyer flasks , with 
0.05% Pluronic F-68 surfactant (Gibco) to prevent clumping of the cells. The flasks were 
incubated at 27⁰C at constant shaking rate of 80rpm. Once cells reached a density of 3.5-
5x106cells/ml, protein expression was induced by adding CuSO4 to a final concentration of 
500µM. After five days the cell supernatant was collected by centrifugation (two spins; first 
at 50 rpm for 10 minutes and second at 2500 rpm for 10 minutes). The supernatant was 
collected and following the addition of 0.02% of Sodium-Azide, stored at 4⁰C. 
 
 
 
 
 
 
 
 
 
 
 
 
Complete growth medium:  Schneiders Drosophila medium + Glutamine 
(Biological Industries) 
    10% FCS (PAA the cell culture company) 
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2.2 Protein Methods 
 
2.2.1 Protein Dialysis  
S2 supernatant was placed into dialysis tubing (cut-off size 12 kDa, Sigma) and dialysed 
against PBS buffer (1:10 ratio) overnight at 4⁰C.   
 
2.2.2 Nickel affinity chromatography 
1ml of Nickel-beads (Ni-NTA agarose stored in 20% ethanol, Qiagen, binding capacity of 
25mg/ml) was added to an Econo column (BIO-RAD). The ethanol was drained off and the 
beads were washed with 10 ml of 1xPBS + 10 mM Imidazole. The dialysed S2 supernatant 
was flown over the beads by gravity at 4⁰C overnight with a slow flow-rate. On the next day, 
the column was washed with 1xPBS + 10 mM Imidazole to remove non-specific proteins. For 
elution of His-tagged proteins, the column was filled with 1xPBS + 250 mM Imidazole (~10 
ml) and left for 30 minutes. After the incubation period the eluted proteins were collected 
in 1ml fractions and quantified by spectrophotometry using UV absorbance (280nm; see 
below).  
 
2.2.3 Protein Concentration and buffer exchange 
For protein concentration Centrifugal Filter units (Millipore) were used, with a molecular 
weight cut off of 10 kDa. The small units (0.5 ml capacity) were centrifuged at 6500 rpm for 
10 minutes at 4⁰C. The large units (15 ml capacity) were centrifuged at 2100 rpm for 20 min 
at 4⁰C. These units were also used for buffer exchange steps, whereby the protein was 
concentrated to a small volume and the units were filled up with the desired buffer and 
centrifuged again. This step was repeated at least three-times to ensure complete buffer 
exchange. 
 
 
 
PBS:  2.7 mM KCl 
137 mM NaCl 
8.1 mM Na2HPO4 
1.76 mM KH2PO4, pH 7.4  
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2.2.4 Quantification of Protein concentration 
Protein concentrations were determined by measuring absorbance at OD280nm using a 
Biophotometer (Eppendorf). The absorbance at OD280nm is a linear function of the molar 
concentration: Abs280 = ε x c x l, whereas ε is the extinction coefficient (L mol
-1 cm-1), c the 
protein concentration (g/l) and l the path length of the sample (mostly l=1cm). If ε is known 
the protein concentration can be calculated from the Abs280 measurement. The absorbance 
of a protein sample at 280 nm is due to Tryptophan (W), Tyrosine (Y) and disulfide bonds 
(SB) within the protein and therefore the ε value of a protein can be calculated by using the 
following formula: ԑ = nW x 5500  + nY x 1490 + nSB x 125. Notably if the disulfide bonding is 
unknown nSB = 0 (Mach, Middaugh, Lewis, 1992). 
 
2.2.5 Size exclusion chromatography 
Protein purification by size exclusion chromatography was performed using a Pharmacia 
FPLC system. For smaller amounts of protein sample (~1 mg) the HR200 column was used, 
whereas for larger amounts (>1 mg) the S200 column was used. Prior to loading protein 
samples, size exclusion columns were equilibrated with the desired buffer (mostly Tris-
buffer). During the gel filtration purification run defined fractions were collected by a 
fraction collector (integrated part of the FPLC system). Elution profiles were generated by 
measuring OD280 of the flow-through. Inspection of the elution profile allowed the 
identification of peak fractions, which were analysed by SDS-PAGE to confirm purity of 
protein samples.    
 
 
 
 
2.2.6 Trichloroacetic acid (TCA) protein precipitation 
To 1 volume of 100 % (w/v) TCA stock 4 volumes of protein sample were added and the 
sample incubated for 10 minutes on ice. The mixture was centrifuged at 14000 rpm for 5 
minutes. The supernatant was removed, without disrupting the protein pellet, which was 
washed twice with 200 µl ice-cold acetone and centrifuged at 14000 rpm for 5 minutes. The 
pellet was dried at 95 ⁰C for 10 minutes.  
Tris-buffer:  50 mM NaCl 
  20 mM Tris, pH 8.5 
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2.2.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated according to size (Laemmli, 1970). For the detection of the Amigo-
fusion proteins (Amigo1-LRR 28 kDa, Amigo1-LRRIg 38 kDa, Amigo3-LRR 28 kDa, Amigo3-
LRRIg 38 kDa) a 15% SDS separating gel was prepared. Normally 10 µg of protein samples or 
TCA precipitated protein pellets were resuspended in SDS Loading buffer containing DTT  
and incubated at 95°C for 10 minutes (reducing conditions = R) or resuspended in Loading 
buffer containing no DTT  and not boiled (non-reducing conditions = NR) before loading onto 
the gel. A voltage was applied across the gel (constant 100 V for the  stacking gel and 150 V 
for the separating gel), for one hour allowing proteins to differentially migrate based on 
their size. Following electrophoresis the gel was stained with Coomassie brilliant blue for 30 
minutes and destained overnight with destain buffer.   
 
 
15% SDS gel:  5ml Bis-acrylamide (30%Acrylamide-0.8% Bis) 
375 µl Tris-HCl, pH 8.8 
100 µl 10% SDS  
100 µl 10% Ammonium Persulfate    
4 µl TEMED made up to 10 ml with distilled water 
 
Stacking gel:  670 µl Bis-acrylamide (30% Acrylamide-0.8% Bis)  
125 µl Tris-HCl, pH 6.8 
100 µl 10% SDS 
40 µl 10% Ammonium Persulfate  
4 µl TEMED made up to 10 ml with distilled water 
 
SDS reservoir buffer: 50 mM Tris 
0.384 M glycine 
0.1% SDS 
 
Reducing 5xSDS loading buffer:  40 mMTris, pH 6.8 
     0.75 % (w/v) SDS 
     8 mM DTT 
 
Non-reducing 5xSDS loading buffer:  40 mM Tris, pH 6.8 
      0.75 % (w/V) SDS 
 
Destain buffer: 20% Methanol 
   10% Acetic Acid  
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2.2.8 Immuno-detection of proteins on nitrocellulose membranes (“Western Blot”) 
Protein samples were first separated by SDS-PAGE as described above. The separated 
proteins were transferred (Towbin et al., 1979) onto a PVDF membrane (Hybond LFP, GE 
Healthcare) for one hour (300V/400mA) using transfer buffer. The efficiency of transfer was 
checked by staining the membrane with Ponceau Red. The membrane was incubated for 
one hour or overnight at 4°C in Blocking Buffer in order to minimize non-specific antibody 
binding. Afterwards the membrane was washed three times with 1xTBS + 0.1 % Tween-20 
for five minutes. The membrane was incubated with the primary antibody diluted in 1xTBS + 
0.1% Tween + 3% BSA for 1 hour at room temperature. The membrane was washed three 
times, each for 5 minutes, with 1xTBS + 0.1 % Tween-20.  The secondary antibody (HRP-
conjugated, anti-mouse,) was added in 5% milk + 1xTBS + 0.1% Tween. Binding was 
visualised by using the “EZ-CCL Chemiluminescence Detection Kit for HRP” (Biological 
Industries). Briefly, this involved mixing 500 µl of solution A with 500 µl solution B and then 
incubating for five minutes at room-temperature. The mixture was added onto the 
membrane and incubated for five minutes at room-temperature. The membrane was placed 
into a cassette and taken to the dark-room, where a light sensitive filter (Amersham 
HyperfilmTM MP, GE Healthcare) was placed for 10 or 20 seconds on the membrane before 
the filter was developed.  
 
Antibody Source Dilution/Animal 
α-Histidine (C-terminal) Invitrogen 1:5000/mouse 
 2nd HRP,  α-mouse IgG  Sigma 1:33333/goat 
Table 2.1: Antibodies used for western blot 
 
 
Transfer buffer:  25 mM Tris  
    192 mM glycine 
20% methanol 
 
Blocking Buffer:  5% dried milk powder 
1 x TBS 
0.1% Tween-20 
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2.3 Functional Studies 
 
2.3.1 Small-scale crystallization trials 
Initial crystallization trials were screened using the “hanging drop vapour diffusion” method 
with the nano-litre Mosquito crystallisation robot (TTP LabTech). To identify the optimal 
conditions for crystal formation three commercial screens (each containing 96 unique 
conditions) were used (Table 2.2). Briefly, 100 µl of crystallization condition was added into 
each well of a 96 well IWAKI plate. The Mosquitorobot was used to pipette nano-litre drops 
(100 nl protein-solution + 100 nl crystallization buffer) onto a 96-well plate seal (TTP 
LabTech). The plate seal was then inverted on to the IWAKI plate such that the appropriate 
drops were placed over their corresponding crystallization buffers. The crystallisation plates 
were incubated at 24°C. After one week the plates were analysed for crystals using a light  
microscope. Conditions that yielded small crystals or needles were selected and optimised. 
For all conditions that provided crystals, negative controls with protein substituted for 
buffer were set up.   
 
Screen Company 
JCSG+ Molecular Dimension 
Wizard I + II Emerald Bio Systems 
Index Hampton Research 
Table 2.2: Commercial Screens used for crystallization trials 
 
2.3.2 Large-scale crystallization trials  
The scale up was performed according to the “hanging drop vapour diffusion method”. In a 
24 well Linbro plate the edges of the wells were coated with vacuum grease  and 1 ml of 
crystallization buffer was added to  each well. On a coverslip 1 µl of crystallization buffer 
was mixed with 1 µl of protein solution. The coverslip was inverted on to the well and 
pushed down so that an air-tight seal was obtained. The plate was incubated for several 
days at 24⁰C before checking for crystals by light microscopy.  
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2.3.3 BIAcore binding analysis 
For the BIAcore protein binding analysis the BIAcore system 3000 with auto-sampler, the 
BIAcore 3000 control software and a CM5 Sensor Chip (GE Healthcare) with four flow-cells 
(FC) were used. A new chip was docked into the system and buffer primed using water and 
normalized with BIAnormalization buffer (GE Healthcare). Following this the buffer was 
changed to the running buffer (HBS-PE). Then the Fc Antibody Rz108ea was amine coupled 
to the surface of all four chambers. Firstly the surface was activated with the EDC/NHS mix 
(10 µl/min for 7min). Secondly the Fc-Antibody ligand was passed over the surface (10 
µl/min for 7min). The surface was saturated with Ethanolamine-HCl (10 µl/min for 7min) 
and finally washed with NaOH (10 µl/min for 7min) and Gly-HCl (10 µl/min for 7min) to strip 
off all non-covalently associated proteins. All four flow chambers were washed with buffer 
at a flow rate of 5µl/min. In the next step recombinant proteins were immobilized. The 
recombinant proteins (NgR-Fc, p75-Fc) were diluted 1:2 in the HBS-EP running buffer and 
injected over appropriate flow-cells (FC 1=no proteins, FC 2=NgR-Fc, FC 3=p75-Fc, FC 4=NgR-
Fc and p75-Fc). After the flow-cell surfaces were prepared the purified protein sample was 
injected and the binding response recorded. 
 
Antibodies/recombinant proteins source concentrations 
α-Fc antibody Antibody production facility, 
University of Birmingham 
25 µg/ml 
NgR-Fc, recombinant human R&D systems 100 µg/ml 
p75-Fc, recombinant human R&D systems 100 µg/ml 
Table 2.3: Antibody and recombinant proteins used for BIAcore analysis 
 
 
 
Solutions for amine coupleing: 5 mM NaOH  
0.1 mM Gly-HCl, pH 2.5 
1 M Ethanolamine 
α-Fc antibody in 10 mM Na-acetate, pH 4.5 
EDC/NHS 1:1 mix (Ethyl-3carbodimide 
hydrochloride/N-Hydroxysuccinimide mix)  
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2.3.4 Cross –linking analysis 
For the Cross-linking of proteins three Cross-linkers with spacer-arms of different length 
were used according to the manufacturers instructions. The cross-linkers were dissolved in 
20 mM Hepes buffer, pH 8.5 and the proteins were diluted in the same buffer.  5-10 µg of 
protein were incubated with 50-fold molar excess of cross-linkers at room-temperature for 
30-60 minutes. The reaction was quenched by the addition of 1 µl of 1 M Tris, pH 8.5.  
 
Cross-linker Source Spacer-arm length 
Dimethyl pimelimidate (DMP) Mike Douglas 9.2 Å 
BS3 Pierce 11.4 Å 
Sulfo-EGS Pierce 16 Å 
Table 3.4:  Reagents used for cross-linking experiments  
 
2.3.5 Deglycosylation of proteins 
The deglycosylation kit (PNGase F, New England BioLabs) was used according to the 
manufacturers instructions. 5-10 µg of protein were diluted with deanaturation buffer and 
heated for 10 minutes at 100 ⁰C. Then the reaction buffer was added to the denatured 
protein, as well as the deglycosylation enzyme. The mixture was incubated at 37⁰C for one 
hour.  
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3. Results 
 
3.1 Can Amigo-proteins substitute for Lingo1 in forming a ternary NgR complex? 
Following CNS injury, myelin derived inhibitors of axonal regeneration bind to the 
NgR/p75/Lingo1 ternary complex on neurons (Yiu and He 2006).  Since Lingo1 is  partially 
responsible for the inhibition of nerve outgrowth and has an expression pattern, which is 
restricted to the CNS, therapeutic strategies to block its function are a potential route 
promoting CNS recovery following injury (McDonald, Bandtlow et al. 2011).  However, 
Lingo1 is only one member of the LRRIg protein family, a set of receptors which share the 
same protein architecture (Ji, Li et al. 2006). Other members of this family, specifically 
Amigo family members, have been shown to be up-regulated following injury to CNS tissue 
(Douglas, M. Personal communication). Furthermore it was possible to co-
immunoprecipitate Amigo1 or Amigo3 with p75 and the NgR (Douglas, M. Personal 
communication). These data suggest that Amigo proteins may substitute for Lingo1 in 
forming a ternary complex with p75 and NgR and therefore play a key inhibitory role in 
response to CNS injury.   
 
3.2 Experimental Approach to study the Amigo proteins 
Previous studies on Lingo1 have highlighted that the functionally important domains include 
the extracellular LRR and Ig domains. As Lingo and Amigo family members share the same 
overall LRR-Ig fold, the Amigo ectodomains were similarly cloned and fused to a His-tag 
sequence to facilitate subsequent purification (Figure 3.1 A).  
At the beginning of the project two constructs were cloned and transfected into cells, 
namely Amigo1 LRR and Amigo 1 LRRIg. Cloning of Amigo3 LRRIg was completed mid-way 
through the project. (Figure 3.1 B).  
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Figure 3.1: Overall expression and purification protocol for the Amigos. (A) Expression vectors, encoding 
either for the His-tagged Amigo-protein or Hygromycin B resistance, were cloned and co-transfected into 
Drosophila S2 cells (carried out by Protein Expression Facility, University of Birmingham). The  stably 
transfected cells were kept in culture and bulked up. After the induction of Amigo protein expression with 
CuSO4, the Amigo proteins were secreted into the supernatant. The supernatant could be harvested by 
centrifugation after five days. The supernatant was dialysed against PBS buffer and the Amigo proteins purified 
by Ni-NTA affinity. To further improve the purity gel filtration chromatography was performed. (B) During this 
project three Amigo constructs were cloned for functional and structural studies. For Amigo1 the whole 
ectodomain containing both the LRR and the Ig domain was cloned, as well as the ectodomain lacking the Ig 
domain. For Amigo3 the whole ectodomain with the LRR and the Ig domain was cloned. 
 
 
 
Figure 3.1: Expression and purification of the Amigo proteins  
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3.3 Purification of Amigo Proteins 
 
3.3.1 Purification of Amigo1 LRR 
To analyse protein expression, 20 µl of supernatant of the Amigo1 LRR culture were taken 
and a western blot was performed using an anti-His antibody, as no characterised anti 
Amigo antibodies are currently available. Robust expression in the supernatant was shown 
(Figure 3.2 A left). Initially, a small volume of supernatant (250 ml) was tested for 
purification. The supernatant was dialysed against PBS and then purified by Ni-NTA 
chromatography, with a yield of 438 µg (1.1 mg out of 1 l). In order to get first hints on 
purity and the native structure of Amigo1 LRR, reduced (R) and non-reduced (NR) samples 
were analysed by SDS-PAGE. No differences between the reduced and non-reduced samples 
could be observed  and although an enrichment of the protein could be observed (arrow) 
the purity was only moderate, with contaminating proteins still visible. (Figure 3.2 A right). 
To improve purity, the next batch of supernatant (250 ml), was proccesed with an additional 
gel-filtration step using a HR200 column (yield after Ni-purification 345 µg, 1.4 mg out of 1l).  
The elution profile (Figure 3.2 B left) yielded three peak fractions all of which were analysed 
by SDS-PAGE to determine which peak corresponded to Amigo1 LRR. The third peak fraction 
contained the Amigo1-LRR protein (arrow), but the purity was still low (Figure 3.2 B right).  
To further increase purity, the Ni-NTA purification protocol was modified by increasing the 
concentration of Imidazole in the wash buffer (from 10 to 20 mM) for the last batch of 
supernatant (500 ml).  Although, the elution profile of the HR200 column now showed only 
two peaks, there was a considerable reduction in protein yield (Figure 3.2 C left). When 
analysing the peak fractions by SDS-PAGE (Figure 3.2 C middle) it was demonstrated that the 
second peak contained Amigo1 LRR in high purity. To confirm the identity of the purified 
protein a western blot was performed using the His antibody (Figure 3.2 C right). In 
conclusion, although pure Amigo1 LRR could be obtained, the final yield was poor. In each 
case after purification, there were only sufficient levels of protein for TCA precipitation and 
analysis by SDS-PAGE.  
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Figure 3.2: Expression analysis and purification of Amigo-1 LRR. (A) Test expression and Ni-NTA purification of 
Amigo1 LRR. Western blot analysis of 20 µl of supernatant (left). SDS-PAGE analysis of fractions following 
purification by Ni-NTA chromatography (right). (B) Optimization of purification. An additional gel-filtration step 
was included to the purification protocol. Elution profile of HR200 column (left). Peak fractions analysed by 
SDS-PAGE (right). (C) Further Optimization of purification. The Ni-beads were washed with 20 mM Imidazole in 
the wash buffer during the Ni-NTA purification step. Elution profile for Amigo1 LRR with the HR200 gel 
filtration column (left). Peak fractions analysed by SDS-PAGE (middle).  The identity of the purified protein was 
confirmed by western blot (right). 
 
 
Figure 3.2:  Expression analysis and Purification of Amigo-1 LRR 
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3.3.2 Purification of Amigo1 LRRIg 
As previously, Amigo1 LRRIg expression was analysed  by western blot using 20 µl of 
supernatant revealing strong expression levels (Figure 3.3 A left). For a small-scale 
purification 250ml of supernatant was dialysed against PBS buffer and purified by Ni-NTA 
and gel filtration (HR200) chromatography (Figure 3.3 A middle). SDS-PAGE analysis 
revealed that the protein was pure even prior to the gel-filtration purification step. No 
differences between the reducing and the non-reducing conditions could be observed 
(Figure 3.3 A right). One striking observation was that on SDS-PAGE gel Amigo1 LRRIg 
migrated  at a higher molecular weight (~45 kDa) than the expected calculated molecular 
weight based on its primary sequence (~38kDa). It was suggested that the protein was 
glycosylated. More remarkably, the protein also eluted much earlier from the column than 
expected for its size. Figure 3.3 B shows the elution profiles of Amigo1 LRRIg and MHC class I 
overlaid following purification by gel filtration (using the S200 column). Although the MHC 
complex (45 kDa, marked by asterisk) is theoretically larger than Amigo1 LRRIg (38 kDa), it 
elutes later (Figure 3.3 B). This potentially suggested that the protein forms a dimer in 
solution. Finally, a large-scale purification (750 ml  supernatant) was purified as described 
above, this time using the S200 gel filtration column. The elution profile provided a single 
peak and the peak fraction analysed by SDS-PAGE demonstrated sufficient levels of purity 
for subsequent studies (Figure 3.3C left and middle). The identity of the purified Amigo 
LRRIg was confirmed by western-blot analysis using His-antibodies (Figure 3.3 C right). From 
one litre of supernatant it was possible to purify ~5 mg of protein after Ni-NTA purification 
and ~2.5 mg after gel-filtration.  
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Figure 3.3: Expression and purification of Amigo1 LRRIg. (A) Test expression and purification. Western blot 
analysis of 20 µl S2 cells supernatant (left). Small-scale purification of Amigo1 LRRIg. 250 ml of S2 cell 
supernatant was dialysed and purified over Ni-beads and gel-filtration column (elution profile of HR200 
column; middle). Analysis of peak fractions by SDS-PAGE following purification by Ni-NTA and gel filtration 
chromatography (right). (B) Overlaid elution profiles of MHC complex (pink) and Amigo1 LRRIg (blue) following 
runs on the HR200 gel-filtration column. Amigo1 eluted unexpected early form the column. (C) Large-scale 
purification. 750 ml of S2 cell supernatant were purified by Ni-NTA and gel filtration (elution profile of S200 
column left side). Analysis of peak fractions by SDS-PAGE following purification with gel filtration (middle). 
Western blot analysis of purified Amigo1 LRRIg  (right). 
 
 
 
 
 
 
Figure 3.3: Expression analysis and Purification of Amigo1 LRRIg 
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3.3.3 Purification of Amigo3 LRRIg 
The expression of Amigo3 LRRIg was tested on 20 µl of S2 cell supernatant by western blot 
analysis using His-antibodies. Although a Ponceau-Red staining indicated that sufficient 
sample was loaded, no signal could be detected, indicating low expression of Amigo3 LRRIg 
(Figure 3.4 A). Despite the low expression levels, a small-scale test purification of Amigo3 
LRRIg was performed. Briefly, 100 ml of supernatant containing Amigo3 LRRIg was dialysed 
against PBS buffer and subsequently purified by Ni-NTA and gel-filtration (HR200) 
chromatography (Figure 3.4B left). Although the elution profile clearly shows a distinct peak 
(arrow), there are several other contaminants present (small peaks preceding the dominant 
peak). Based on the overlay of the elution profiles of Amigo1 LRRIg and Amigo3 LRRIg 
(Figure 3.4 B right) it was evident that Amigo3 LRRIg elutes at a similar place to Amigo1 
LRRIg, showing the same shift of early elution. For this reason only the peak fraction (arrow) 
was collected and analysed by SDS-PAGE (Figure 3.4 C left). No differences between the 
reduced and non-reduced samples could be observed and although after gel-filtration 
Amigo3 LRRIg showed a higher degree of purity, there were still background proteins 
present.  Overall, the protein was pure enough to continue with further experiments. As 
before, a western blot analysis on the purified protein using His-antibodies was performed 
to confirm its identity (Figure 3.4 C right). The total yield of the protein was lower than that 
for Amigo1 LRRIg, which was not surprising as the expression levels were considerably 
lower. After Ni-NTA purification, with 400 ml of supernatant, a total protein yield of 1.9 mg 
was obtained (~4.8 mg per/l) and after gel-filtration 78 µg of protein were purified. The high 
amount of protein found after Ni-NTA purification does not correspond with the finally 
purified protein amount. As the protein expression could not be detected on  western blot 
and the elution profile of the gel-filtration column showed a lot of impurities, it is likely, that 
the OD reading of Amigo3 LRRIG was therefore falsely high, manipulated by unspecific 
bound  proteins.  
 
 
 
 
 
 
 
 
70 
 
 
 
 
 
 
 
Figure 3.4: Expression and purification of Amigo-3 LRRIg. (A) Test expression of Amigo3 LRRIg. Western blot 
analysis of 20 µl S2 cells supernatant cells. (B) Test purification. 100 ml of supernatant was dialysed and 
purified with Ni-NTA and gel-filtration (elution profile of HR200 column; left). An overlay of Amigo1 LRRIg and 
Amigo3 LRRIg elution profiles (HR200 column, right). (C) Control of purification. 20 µl of supernatant and 8 µg 
of either Ni-bead purified protein (-HR200) or additionally gel filtered protein (+HR200) was loaded on a gel (in 
reducing (R) or non-reducing (NR) conditions, stained with Coomassie, left side). Western blot analysis of 
purified Amigo3 LRRIg (right). 
 
 
 
 
Figure 3.4:  Expression analysis and Purification of Amigo3 LRRIg 
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3.4 Functional studies   
 
3.4.1 Mass-spectrometry analysis of Amigo1 LRRIg and Amigo3 LRRIg 
To confirm the identity of the purified proteins, western blots with His-antibodies had been 
performed. This is an indirect proof utilizing the His-tag of the fusion protein. To obtain 
direct evidence that Amigo1 LRR Ig and Amigo3 LRRIg were purified, bands from SDS-PAGE 
gel were excised and sent to be analysed by mass spectrometry (Helen Copper, Biosciences).  
For Amigo1 LRRIg a peptide coverage of 85% was observed and for Amigo3 LRRIg a peptide 
coverage of 90% of the cloned protein sequence could be achieved, thereby providing a 
direct confirmation of the identity of the purified proteins (Figure 3.5). 
 
3.4.2 Deglycosylation of Amigo1 LRRIg and Amigo3 LRRIg 
The expected sizes of Amigo1 LRRIg and Amigo3 LRRIg, calculated based on their primary 
amino acid sequence, were ~38 kDa. On SDS-PAGE the Amigo proteins migrated at a size 
corresponding to ~45 kDa. This led to the suggestion that these proteins may be 
glycosylated. To test this hypothesis Amigo1 and Amigo3 LRRIg were treated with the 
deglycosylation enzyme PNGase F (Figure 3.6 A). In the treated samples smaller bands (~40 
kDa) appeared, resulting from the removal of the glycosyl-groups. The confirmed protein-
glycosylation would explain the larger size of the proteins on SDS-PAGE.   
 
3.4.3 Cross-linking of Amigo1 LRRIg and Amigo3 LRRIg 
As noted earlier during gel-filtration both Amigo proteins eluted earlier from the column 
than expected for their size. This led to the suggestion that Amigo proteins may form dimers 
in solution. To address this, cross-linking experiments were performed. For these cross-
linking experiments the Tris-buffer could not be used as it is a primary amine and would 
interfere with the cross-linking process, in which Lysines are covalently linked by the cross-
linker. Therefore, Amigo1 LRRIg and Amigo3 LRRIg were purified in the presence of Hepes 
buffer pH 8.   
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Figure 3.5: Mass-Spectrometry data for Amigo1 LRRIg and Amgio3 LRRIg. Samples of Amigo1 LRRIg and 
Amigo3 LRRIg were excised from a a SDS-PAGE and sent for analysis by mass-spectrometry. The whole protein 
sequences for Amigo1 and Amigo3 are shown. The relevant protein sequences, as cloned, are separated by // 
and marked with yellow. The peptides, which were detected by mass-spectrometry, are indicated in green. For 
Amigo1 LRRIg and Amigo 3 LRRIg, a coverage of 85 and 90 % was achieved.  
 
 
 
 
 
Figure 3.5: Mass-Spectrometry data for Amigo1 LRRIg and Amgio3 LRRIg 
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Figure 3.6: Deglycosylation and cross-linking of Amigo1 and Amigo3 LRRIg. (A) Removal of Glycosyl-groups of 
protein. Amigo1 LRRIg and Amigo3 LRRIg were treated with PNGase F, which cleaves protein glycosyl-groups. 
Samples were loaded on a gel and stained with Coomassie. (B) Cross-linking analysis for dimerisation. MHC 
complex (left) Amigo1 LRRIg, Amigo3 LRRIg (right) were treated with BS
3
 and analysed by SDS-PAGE.  Samples 
were taken at indicated time points 
 
 
 
.   
 
 
 
Figure 3.6: Crosslinking and Deglycosylation of Amigo1 and Amigo3 LRRIg 
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The MHC complex (45 kDa, composed of a heavy chain (33kDa) and a light chain (12 kDa)) 
was selected as a positive control for the cross-linking experiments. Initial cross-linking trials 
with DMP(DimethylPimelidate) failed to cross-link either the MHC complex or the Amigo-
proteins (data not shown). Analysis of the MHC protein structure revealed that the lysines 
were at least 10 Å apart and that the spacer arm of DMP (9.2 Å) was too short to connect 
them. For this reason two cross-linkers with longer spacer arms (BS3=11.4 Å and SEGS=16 Å) 
were tested. Both cross-linkers worked and the results for BS3 shown in Figure 3.6 B.  
Following the cross-linking experiment with the MHC complex, a band around 45kDa is 
observed (Figure 3.6 B left). For Amigo1 LRRIg, the negative control displays a native 45kDa 
band, while in the cross-linked samples a bigger ~100 kDa band is observed (Figure 3.6 B 
right). This suggests that Amigo1 LRRIg can exist as a dimer in solution and porvides a likely 
explanation for the early shifts in elution during gel filtration chromatography. In contrast, 
for Amigo3 LRRIg, no differences in the negative control or the cross-linked samples could 
be observed (Figure 3.6 B right).  
 
3.4.4 BIAcore binding analysis of Amigo1 LRRIg and Amigo3 LRRIg 
To prove if Amigo proteins may substitute for Lingo1 in forming a ternary complex with p75 
and NgR, direct binding of Amigo proteins to NgR or p75 was tested by BIAcore. Briefly, NgR-
Fc and p75-Fc were coupled to the surface of the sensor chip and the Amigo proteins in Tris-
buffer were injected over the flow cells. Ni-NTA purified Amigo protein samples, were 
initially tested (Figure 3.7 A and C). However, these samples were adhering non-specifically 
to the flow-cell surface and therefore could not be used. Amigo protein samples that were 
additionally gel-filtrated after the Ni-NTA purification, were available, although at a lower 
concentration. Samples purified by gel filtration did not stick as before (Figure 3.7 B, D and 
E), but the results were still inconclusive. Certainly a stable protein-protein interaction 
analogous to that proposed between LINGO-1 and NgR (Mosyak, Wood et al. 2006) could be 
excluded, as the off-rate was too fast. At present, based on the binding data a weak protein-
protein interaction between the Amigo proteins and NgR-Fc, involving a fast off-rate, cannot 
be excluded. For example, during the binding phase, for Amigo1 LRRIg (0.48 mg/ml) a 
response of 20 units to the NgR-Fc (Figure 3.7 B) was observed. In comparison for Amigo3 
LRRIg (0.4 mg/ml) a larger binding response of 75 units were evident (Figure 3.7 D). Also, 
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injection of lower concentrations of Amigo3 LRRIg (0.1 mg/ml) over a flow cell with NgR-Fc 
led to a smaller binding response of 20 units (Figure 3.7 E).  Interestingly, in the flow-cell 
coated with NgR-Fc and p75-Fc, a small binding response was visible (40 units for Amigo3 
LRRIg 0.4 mg/ml (Figure 3.7 D), 10 units for Amigo3 LRRIg 0.1 mg/ml (Figure 3.7 E)). 
However, in the flow-cell that was coated with p75-Fc, no binding response was visible for 
either Amigo proteins. The buffer control (Figure 3.7 F) demonstrated that the flow-cells 
were coated with similar levels of protein on their surfaces. Although such signals are 
relatively low compared to the level of NgR-Fc and p75-Fc immobilised, these results do not 
rule a weak protein-protein interactions between the tested Amigo proteins and NgR out. 
However, further experiments are needed to unequivocally prove that Amigo proteins bind 
to NgR and p75.  
 
3.4.5 Crystallisation Trials of Amigo1 LRRIg 
To determine the three dimensional structure of the Amigo proteins by X-ray 
crystallography, protein crystals were needed. For the crystallisation trials were limited to 
Amigo1 LRRIg as it was available in suitable quantities and sufficiently pure. To grow protein 
crystals the protein molecules in solution need to specifically interact with each other.  The 
components in a crystallization solution (buffer, salt and precipitant) support this process, 
but vary for each protein. To identify the optimal crystallization solution for Amigo1 LRRIg, 
three commercial screens  were tested on a small scale using the “Hanging Drop vapour 
diffusion method”. Following the initial crystallisation screening trials, three conditions 
yielded possible signs of crystals after one week (Figure 3.8 A). The trials were repeated on a 
small-scale with the most promising condition (JCSG+ 1.20; 0.2 M MgCl2, 0.1 M Tris pH 8, 
10% PEG 8000). In most of the drops multiple crystals were observed, of a size of ~40x40 
microns (Figure 3.7 B left and middle), while in the negative controls, in which the protein 
solution was replaced by crystallization buffer, no crystals were observed (Figure 3.8 B 
right). These crystals were too small for X-ray diffraction experiments, as typically a 
minimum size of ~100x100 microns is needed. The crystallization process with the identified 
condition was therefore scaled up. However, initial large scale attempts, using the last 
amounts of purified Amigo1 LRRIg protein, failed to yield crystals with only aggregates 
found in the drops. In order to optimise the crystallization process different variations of the 
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methods were tested. (I) The protein concentration of Amgio1 LRRIg (normally 10mg/ml) 
was varied between 9 mg/ml and 7 mg/ml as well the amount of PEG 8K (from 10% to 
7.5%). (II) Protein:crystallisation buffer drop sizes were varied  from 100+100 nl to 
200+200nl and 400+400nl. (III) the drop ratio of protein solution and crystallization buffer 
was varied (from 1:1 to 1:2 and 1:3). (IV) “sitting drop vapour diffusion method”, in which 
the drops were place on a bridge over the buffer reservoir, was tested. (V) The large scale 
up was repeated using commercial conditions rather than using the home-made condition. 
These modifications, finally using the commercial condition and using a new batch of 
purified Amigo 1 LRRIg protein, led to the growth of crystals after one week, which were 
large enough to attempt initial X-ray diffraction experiments (Figure 3.8 C).  
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Figure 3.7: BIAcore binding analysis of Amigo1 LRRIg and Amigo3 LRRIg. 
Flow cells, coated either with NgR-Fc (blue), p75-Fc (red), NgR-Fc and p75-Fc (green) or Fc-Antibody  alone 
(negative control, black) were injected with  
Ni-NTA purified Amigo1 LRRIg.  
Ni-NTA purified, gel-filtrated Amigo1 LRRIg. 
Ni-NTA purified Amigo3 LRRIg.  
Ni-NTA purified, gel-filtrated Amigo3 LRRIg.  
Ni-NTA purified, gel-filtrated Amigo3 LRRIg.   
Hepes buffer. 
 
 
Figure 3.7: BIAcore binding analysis of Amigo1 LRRIg and Amigo3 LRRIg 
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Figure 3.8: Crystallization trials for Amgio1 LRRIg. (A) Crystallisation conditions that have yielded Amigo1 
LRRIg crystals using the hanging drop vapour diffusion method. (B) Small-scale trials with JCSG+ condition 1:20. 
Crystals of Amigo1 LRRIg (40x40 microns) were grown (left and middle) but no crystals were observed in the 
negative control (right). (C) Large-scale trials with JCSG+ condition 1:20 with 1:1 (left) and 1:3 (right) ratio 
drops (protein:crystallisation buffer). The crystals reached a size of ~100x100 microns.  
 
Figure 3.8: Crystallization trials for Amigo1 LRRIg 
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4. Discussion 
In the CNS only limited regeneration is observed following injury, partly resulting from the 
action of myelin derived inhibitors (MAG, Nogo, OMgp), which all bind to the Nogo-receptor 
complex, consisting of NgR, p75 and Lingo1 (Filbin 2008). Lingo1 is one member of a large 
group of CNS enriched membrane proteins, with a LRR and an Ig domain in their 
ectodomain. Other members of this LRR-Ig protein family include the Amigo-proteins, which 
have previously been described in the context of neuronal development and survival (Kuja-
Panula, Kiiltomaki et al. 2003; Ono, Sekino-Suzuki et al. 2003). Little is known about the 
molecular mechanisms governing Amigo protein function within the CNS. Recent microarray 
experiments showed up-regulation of specific Amigo proteins following CNS injury, 
suggesting that these LRR-Ig folded proteins could be relevant to the CNS injury response 
and/or regenerative pathways (M. Douglas, personal communication). An interaction of the 
Amigo-proteins with NgR and p75 could be demonstrated by Co-immuoprecipitation studies 
(M. Douglas, personal communication). This data suggested that the Amigo-proteins may 
substitute for Lingo1 in forming a ternary NgR complex. In this project this hypothesis was 
examined using a combination of biochemical, binding and structural approaches.  
 
4.1 Purification of Amigo ectodomains 
To gain an in-depth understanding of Amigo function, the entire ectodomains of Amigo 
proteins 1, 2 and 3 (LRR and the Ig domain) as well as a shorter ectodomain (containing only 
the LRR domain)  should be  expressed in recombinant form. However, due to time 
constraints for this project three constructs were cloned. These include the short 
ectodomain of Amigo1 (Amigo1 LRR), and the entire  ectodomains of Amigo1 (Amigo LRRIg) 
and Amigo3 (Amigo3 LRRIg). Initially, these constructs were expressed and purified for 
subsequent functional and structural analysis. The results varied significantly for each 
construct. Amigo1 LRR showed very good levels of expression based on the western blot 
analysis of the S2 supernatant. However, following Ni-NTA purification it was found to be 
impure containing a number of unspecified  contaminating proteins and as a result the 
purification conditions were modified to increase the purity of the protein. The final 
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optimised purification procedure for Amigo1 LRR- consisted of increasing the Imidazole 
concentration (from 10-20mM) in the wash step (to remove non-specific proteins) followed 
by gel filtration chromatography. Despite producing pure Amigo1 LRR, much protein was 
lost such that further studies could not be carried out. One potentiallly interesting aspect 
would be to examine whether the other Amigo proteins (2 and 3) with similarly truncated 
ectodomains behave in a similar manner to Amigo1 LRR. If they behave in a comparable 
way, it may suggest that the Amigo LRR domains on their own are not very stable and 
increasingly prone to forming aggregates and unspecific interactions. To overcome this 
problem it may be worth re-engineering the protein and extending the flanking regions or 
adding another fusion tag (eg. GST). If this does not work, a slightly different approach could 
examine the structural properties of an ectodomain lacking the LRR domain.  
In contrast, the whole ectodomain of Amigo1 was stably expressed and could be easily 
purified with high yields of pure protein.   
 Intriguingly, Western blot analysis of Amigo3 LRRIg expression showed no signal, although 
other signals on the same blot were clearly visible. The membrane when stained with 
Ponceau-Red revealed that adequate material was loaded and that the blotting had worked. 
This may suggest that overall expression levels of Amigo3 LRRIg are low. This finding is in 
contrast to the OD reading performed after Ni-NTA purification of 400 ml of supernatant, 
which revealed a yield of ~2 mg of protein. An explanation would be that the protein was 
very impure and falsified the measurement. The elution profiles of the gel-filtration columns 
support this, as they revealed a much unspecific protein attached to Amigo3 LRRIg. The final 
yield of protein was further reduced once impurities were separated from the Ni-NTA 
purified protein sample by gel filtration chromatography. Nevertheless, there was sufficient 
Amigo3 LRRIg protein available for functional studies.  
It was observed, that the protein was not stable in PBS buffer and formed aggregates or 
precipitates after thawing. The pH of PBS is close to the predicted isoelectric points of the 
Amigo proteins, leaving them without charge and therefore possibly unstable in solution. 
For this reason all Amigo proteins were transferred into Tris-buffer with a higher pH. 
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4.2 Functional Analysis of Amigo1 LRRIg and Amigo3 LRRIg 
During the purification process it was evident that the Amigo proteins migrated aberrantly 
on a SDS-PAGE gel. Based on their primary amino sequences a molecular weight of ~38 kDa 
was calculated, but on the SDS-PAGE gel bands corresponding to ~45 kDa were observed. 
This led to the suggestion that the Amigo LRRIg proteins may be post-translationally 
modified by glycosylation. To test this Amigo1 and Amigo3 LRRIg were treated with a 
deglycosylation enzyme, which proved that these proteins were glycosylated.  
Another striking observation during purification was that Amigo proteins eluted earlier than 
expected from the gel filtration column. This effect could have been due to the overall 
shape, which beside the size can influence the protein elution profile. Alternatively Amigo 
LRRIg proteins may exist as oligomers in solution. This would be consistent with structural 
studies of Lingo1, which suggested that Lingo1 forms tetramers in solution and confirmed it 
by cross-linking experiments (Mosyak, Wood et al. 2006). Although the non-reduced 
samples on the SDS-PAGE gel run as monomers, it could not be ruled out that they exist as 
oligomers in solution. To further clarify this issue, cross-linking analyses was performed on 
the Amigo 1 and 3 LRRIg proteins. Three different cross-linkers, with different length spacer-
arms were used. After the initial failed  attempts with DMP (9.2 Å spacer arm), cross-linking 
was successfully performed using the reagents BS3 and Sulfo-EGF (11.2 and 16 Å spacer-
arms) including the positive control (MHC complex), indicating that the method was 
working. For Amigo1 LRRIg, a cross-linked band corresponding to ~100 kDa was visible, 
suggesting that Amigo1 LRRIg can form high order oligomers (most probably dimers) in 
solution.  
In contrast, for Amigo3 LRRIg no evidence for dimerisation could be observed in all 
attempted cross-linking experiments. It is therefore possible that Amigo3 LRRIg does not 
oligomerize. However, Amigo3 LRRIg eluted similarly to Amigo1 LRRIg upon gel filtration, 
and so this lack of evidence for a oligomer should be treated with caution. One limitation to 
this result is that limited protein of lower purity was available for the cross-linking 
experiment (4 µg instead of the recommended 5-10 µg), which may have had an effect on 
the final result.  In addition, such cross-linking approaches rely on the presence of 
appropriate functional groups on Amigo 3 LRRIg, which may have been absent. Therefore, 
the cross-linking experiments for Amigo3 LRRIg need to be repeated, preferentially with 
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more and purer protein, and possibly with alternative cross-linkers, before a more 
conclusive statement can be made. In either case for the future a more definitive answer on 
the oligomerisation status of Amigo LRRIg proteins could be provided by analytical 
ultracentrifugation.  
BIAcore technology was used to examine whether Amigo proteins can directly  bind to NgR 
or p75 and form a ternary complex, as was demonstrated for Lingo1 (Mosyak, Wood et al. 
2006). This involved injecting purified Amigo proteins over flow cells coated with NgR-Fc and 
p75-Fc. Although these results proved inconclusive, a stable protein-protein interaction 
could clearly be ruled out, as the off-rate was too rapid. This may not be surprising since for 
NgR and p75 to assemble with a Amigo protein a weak interaction may be sufficient, as they 
are all membrane surface proteins and therefore in close contact to each other. During the 
injection phase a small binding response was evident for the flow cells, coated with NgR-Fc. 
For the flow cells coated with p75, however, no binding at all could be demonstrated.  There 
are several points to take into consideration before repeating the BIAcore experiments. 
Firstly the flow cells were coated with slightly different amounts of proteins. This would not 
be a problem for a high affinity protein interaction, but could make a significant difference 
in the detection of weak interactions. Secondly, the coating of flow cells with Fc-antibodies 
could have placed the NgR and p75 in a sterically unfavourable position, thus preventing the 
Amigo proteins from binding optimally. Alternatively, the NgR-Fc and p75-Fc proteins may 
be functionally inactive. To confirm or to rule out a weak interaction between the three 
proteins a modified protocol could involve injecting Amigo proteins over NgR and p75 
immobilised on streptavidin rather than using Fc proteins. This strategy might conceivably 
counteract the steric hindrance related issue. Also, to rule out the possibilities that the 
putative Fc ligands are inactive, a positive control is required for the BIAcore experiments. In 
this case the Lingo-1 ectodomain would be a good candidate, as previous studies have 
demonstrated direct binding between Lingo-1 and NgR-Fc (Mosyak, Wood et al. 2006).  
Finally, the Tris buffer provided a negative buffer signal which is less favourable for 
detecting weak interactions. It may be more desirable to use a different buffer that gives a 
positive buffer signal, as smaller response differences are better detected in buffers that 
yield a positive signal. 
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Preliminary experiments designed to produce crystals for structural studies of Amigo1 LRRIg 
were performed. Initial screening trials using the mosquito nano-litre crystallisation robot 
identified several conditions that yielded potential crystal hits. The best hit was then 
optimised and scaled up. The crystallisation trials were successful with one condition 
yielding crystals that are sufficient in size for subsequent X-ray diffraction experiments. 
Similar tests will be performed for the other Amigo proteins, when sufficient amounts of 
purified proteins are available. 
 
4.3 Concluding remarks 
The aim of the project was to examine whether Amigo proteins could substitute for Lingo1 
and directly bind to NgR and p75 and form a ternary complex. As discussed above Amigo1 
LRRIg and Amigo3 LRRIg were expressed and purified. Currently, Amigo2 LRRIg and Lingo1 
LRRIg are at the cloning stage and will be expressed, purified and tested to gain further 
insights into the function of Amigo family members.  However, based on this project it has 
not been possible to conclude whether the Amigo proteins can substitute for Lingo1 in 
forming the NgR complex and further studies are needed.  
A second aim was to initiate structural studies for Amigo proteins to determine their three 
dimensional structure.  For Amigo1 LRRIg considerable progress has been made with the 
growth of crystals that are sufficient in size for preliminary X-ray diffraction experiments.   In 
further studies in this field one important consideration is the potential complexity of the 
Nogo-receptor complex. This complexity results from the fact that two more isoforms of the 
Nogo-receptor, namely NgR2 and NgR3, exist, which have overlapping but distinct 
distributions in the matured CNS (Venkatesh, Chivatakarn et al. 2005; Chivatakarn, Kaneko 
et al. 2007). Their potential importance is seen with the observation that the loss of NgR1 is 
not sufficient for attenuating MAG inhibition (Venkatesh, Chivatakarn et al. 2007). It would 
also be possible that the Amigo proteins interact with NgR2 or NgR3 rarther than NgR1, 
which was examined here. Thus future binding experiments should include testing whether 
Amigo proteins bind to these isoforms.  
It is therefore possible, that the formation of the NgR complex, and resultant functional 
properties is far more complicated than currently appreciated. It is likely that this area of 
research will continue to be the subject of intense study for many years to come. 
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